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No previous review has formally modelled the decline in IHD risk following quitting smoking. From Pub-
Med searches and other sources we identiﬁed 15 prospective and eight case-control studies that com-
pared IHD risk in current smokers, never smokers, and quitters by time period of quit, some studies
providing separate blocks of results by sex, age or amount smoked. For each of 41 independent blocks,
we estimated, using the negative exponential model, the time, H, when the excess risk reduced to half
that caused by smoking. Goodness-of-ﬁt to the model was adequate for 35 blocks, others showing a
non-monotonic pattern of decline following quitting, with a variable pattern of misﬁt. After omitting
one block with a current smoker RR 1.0, the combined H estimate was 4.40 (95% CI 3.26–5.95) years.
There was considerable heterogeneity, H being <2 years for 10 blocks and >10 years for 12. H increased
(p < 0.001) with mean age at study start, but not clearly with other factors. Sensitivity analyses allowing
for reverse causation, or varying assumed midpoint times for the ﬁnal open-ended quitting period little
affected goodness-of-ﬁt of the combined estimate. The US Surgeon-General’s view that excess risk
approximately halves after a year’s abstinence seems over-optimistic.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
It has long been known that smoking increases the risk of
ischaemic heart disease (IHD), often referred to as coronary heart
disease (CHD), and that the excess risk (i.e. the increase in relative
risk (RR) compared to that in never smokers) declines on quitting
smoking (US Surgeon General, 1979). However the time-pattern
of decline in excess risk following quitting has never been precisely
characterized, and statements made by authorities have varied.
Thus, some years ago, the US Surgeon-General stated (1979) that
‘‘cessation of smoking reduces the risk of mortality from coronary
heart disease, and after 10 years off cigarettes this risk approaches that
of the nonsmoker’’, and 11 years later (1990) that ‘‘the excess risk of
CHD caused by smoking is reduced by about half after 1 year of smok-
ing abstinence and then declines gradually. After 15 years of absti-
nence, the risk of CHD is similar to that of persons who have never
smoked.’’ More recently, in a Monograph ‘‘Reversal of risk after quit-AD, coronary artery disease;
; DF, degrees of freedom; H,
Cancer; IHD, ischaemic heart
ative risk; SE, standard error.
-NC-ND license.ting smoking’’, the International Agency on Research and Cancer
(IARC) (2007) examined the evidence in considerable detail, noting
that ‘‘Some studies ﬁnd the risk to be similar to that in never smokers
after 10–15 years abstinence, whereas others ﬁnd a persistent in-
creased risk of 10–20% even after 10–20 years.’’ After noting a num-
ber of methodological issues in assessing this evidence, such as the
problem of reverse causation with some smokers quitting because
of disease and the difﬁculties in accurately assessing smoking ha-
bits, they pointed out that ‘‘the body of evidence points toward the
risk of CHD asymptotically approaching the risk of never smokers.’’
All the published assessments of the decline in excess risk are
limited by being based on an impression gained from inspection
of how the estimated RR, and its 95% conﬁdence interval (CI), var-
ies by time of quitting smoking, with no formal method used to ﬁt
curves to the declining pattern, or test whether patterns vary be-
tween studies. We attempt to rectify this omission by ﬁtting, sepa-
rately for each available data set satisfying certain deﬁned criteria,
a simple model to the observed decline. This model, the negative
exponential, predicts that the risk asymptotically approaches the
risk of never smokers, as suggested in the IARC Monograph
(2007), and characterizes the shape of the curve by a single para-
meter which can be used to assess variation between studies. This
parameter, the half-life (H), is the time at which the excess risk of a
quitter reaches half that of a continuing smoker. While there are
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discussion, we believe that the analyses that we describe give some
support for this model, and suggest its possible application to de-
scribing risk patterns following quitting for other smoking-related
diseases, and perhaps also to describing risk patterns following
other changes in smoking habits, such as reducing the amount
smoked, or switching to a reduced exposure product.2. Materials and methods
2.1. Inclusion and exclusion criteria
Attention was restricted to epidemiological prospective or case-
control studies which presented data by time of quitting smoking
on mortality or incidence of IHD, CHD, or acute myocardial infarc-
tion (AMI). The data had to be available in a form that allowed ﬁt-
ting of the negative exponential distribution, as described in the
statistical methods below. Studies of effects of quitting following
an AMI were excluded, as were studies which only presented re-
sults for total cardiovascular disease, including cerebrovascular
disease.2.2. Literature searches
In November 2009, relevant papers were sought from the
Monograph on smoking cessation by IARC (2007), which was based
on an extensive literature review. Additional papers were also
sought from some earlier reviews of the epidemiology of heart dis-
ease and smoking (Lee, 2001; US Surgeon General, 1979, 1990,
2004), and from ﬁles on smoking and health accumulated over
many years by P N Lee Statistics and Computing Ltd. A PubMed
search was then carried out using the search terms ‘‘(quitting
smoking OR former smoking OR ex smoking) AND (coronary heart
disease OR ischaemic heart disease OR acute myocardial infarc-
tion)’’ to check for additional references in the previous three
years. Papers were also sought from references cited in papers ob-
tained. A further PubMed search was carried out in October 2011,
also limited to the previous three years, but using the same search
terms.2.3. Identiﬁcation of studies
Relevant papers were allocated to studies, taking into account
multiple papers from the same study, and papers reporting on
multiple studies. Each study was given a unique reference code
(REF) of up to 6 characters, often based on the principal author’s
name, but sometimes based on the name of the study. Care was ta-
ken to try to avoid different allocated studies involving the same
groups of subjects, which would lead to double-counting in the
meta-analyses. However, limited overlap of subjects in different
studies was allowed in some situations, where the alternative
would have meant considerable loss of power. Where necessary,
additional details of the studies were obtained from other publica-
tions describing them.2.4. Data recorded
For each study, relevant information was entered onto a study
database and a linked RR database. Note that, throughout this pa-
per, the term RR is used to include its various estimators, including
the odds ratio and the hazard ratio. The study database contains a
record for each study describing the relevant publications, sexes
considered, age range, populations and race(s) considered, loca-
tion, timing, length of follow-up, study design, disease deﬁnitionand fatality, types of controls, numbers of cases, and numbers
either of controls or in the at risk population.
The data entered on the RR database relates to sequences of RRs
(‘‘blocks’’). A block may consist of an RR for current smokers and a
set of RRs for ex smokers by period of quitting, with each RR ex-
pressed relative to never smokers. Alternatively, it may consist of
an RR for never smokers and a set of RRs for ex smokers by period
of quitting, with each RR expressed relative to current smokers.
The data recorded on the database for each RR included the block
number, RR number within study, source reference details, sex, age
range, race, smoking status (current, ex or never smoked, and for
ex smokers the lower and upper times of quitting for each quitting
period), product smoked (any product, cigarettes only, cigarettes
+/ other products), comparison group (never or current smoker
of any product, cigarettes or undeﬁned), deﬁnition of disease,
length of follow-up and adjustment variables, as well as the RR
and its 95% CI and, for unadjusted data, the numbers of cases and
controls in the numerator (‘‘exposed group’’) and denominator
(‘‘unexposed group’’). Also recorded was how the RR was derived
(as given originally, from numbers, or taken from a graph) as well
as whether the never smoking comparison group allowed for the
inclusion of smokers of up to a minimum amount, as well as other
information required for the statistical estimations to be carried
out (as described in the next section).
Lower and upper times of quitting for successive quitting peri-
ods were recorded so that they ran on continuously. Thus, for
example, an upper limit for a range given as 5–9 years, where
the next range given had a lower limit of 10 years, was recorded
as 10 years, as it was felt that the given range of 5–9 years included
values of up to 9.999 years. Open-ended upper limits for the lon-
gest quitting period were entered as 999 years. Where the lower
limit for the earliest quitting period was given as greater than
0 years, this value was entered directly. Thus, for an earliest period
given as 1–5 years, it was assumed that quitters of less than 1 year
had not been included. In many, but not all of these cases, the
source papers had speciﬁcally noted that those who had quit for
less than the lower limit had been excluded from analysis (or in-
cluded among the current smokers). Values were entered as years,
with values given as months converted to decimal years.
2.5. Statistical methods
2.5.1. Pseudo-numbers
The ﬁrst step, for each block, was to use the method of Hamling
et al. (2008) to estimate the pseudo-table of the numbers of cases
and the numbers either in the at risk population (for prospective
studies) or of controls (for case-control studies) that correspond
to the observed RRs and 95% CIs. Whether the RRs were originally
expressed as relative to never smokers or relative to current smok-
ers, the estimated pseudo-table consisted of a number of cases (nj)
and of controls or at risk (Nj) for never smokers, current smokers
and quitters, by period of quitting. The subscript j is deﬁned as 0
for never smokers, and runs from 1 to k for the quitting and current
smoking groups. The estimation of the pseudo-table requires, in
addition to the given RRs and 95% CIs, estimates of the proportion
unexposed among the controls (or at risk) and of the ratio of total
controls (or at risk) to total cases, as well as starting values for the
number of unexposed cases and of controls (or at risk). These esti-
mates had been entered on the database. The pseudo-table forms
the data for ﬁtting the negative exponential distribution.
2.5.2. Fitting the negative exponential distribution to data for
prospective studies
The data ﬁtted for each smoking group j in the block consists of
the (pseudo-table) number of cases (nj) and of at risk (Nj) together
with an estimate of the time of quit (tj). tj is taken to be inﬁnite for
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midpoint time of the interval for ex smokers. Unless estimates of
tj were provided by the authors (in fact, never the case), the mid-
point was estimated, for closed intervals, by the mean of the limits
of the speciﬁed range of time quit. For intervals that were open-
ended above, tj was estimated as the mean of the lower limit and
either 50 years or the upper limit of the age range studied minus
20 years, if this was smaller than 50 years. The value of 50 years
is an approximate estimate based on data from older populations
for those studies that give a detailed distribution of time of quit.
However given that smokers are unlikely to start and quit smoking
before age 20 years, the estimation also takes into account that
assuming a 50 year upper limit might not be sensible for studies
of younger populations.
The underlying model to be ﬁtted to data from a block is of the
form
Pj ¼ Aþ BexpðCtjÞ ð1Þ
where Pj is the absolute risk of disease at time tj in group j and A, B
and C are parameters to be estimated. Here A is the risk in never
smokers, A + B is the risk in current smokers, and B is the increase
in risk for current smoking. The term exp(Ctj) models the propor-
tional decline in excess risk for ex smokers, declining asymptoti-
cally from 1 to 0, as time increases. H is estimated by
0:5 ¼ expðCHÞ ð2Þ
or
H ¼ ðloge2Þ=C: ð3Þ
To estimate the parameters A, B and C, maximum likelihood
methods were used. For each smoking group, the contribution to
the log-likelihood function, Lj, (ignoring terms that do not vary in
A, B or C) is given by
Qj ¼ log Lj ¼ nj log Pj þ ðNj  njÞ logð1 PjÞ: ð4Þ
The overall log-likelihood for the block summed over the smok-
ing groups, L, is then maximized using Newton–Raphson methods.
For a sample of the data, these estimates were conﬁrmed using Ex-
cel’s solver routines based on the GRG2 algorithm (Lasdon et al.,
1978) to maximize the likelihood. Formulae for the ﬁrst and sec-
ond derivatives of the log-likelihood with respect to A, B and C,
and hence estimates of the variances of A, B, C and H, have been de-
rived and are available on request. Goodness-of-ﬁt to the model
may be assessed by comparing the ﬁtted value of L, with that for
the maximum value possible (‘‘best-ﬁt model’’), obtained by
substituting Pj = nj/Nj in the formula for Qj above.
2.5.3. Fitting the negative exponential distribution to data for case-
control studies
The data ﬁtted for each smoking group j in the block consists of
the number of cases (nj), the number of controls (Nj) and the times
of quit (tj), with the times of quit estimated as for prospective stud-
ies. Here, however, the model used is
Fj ¼ 1þ B expðCtjÞ ð5Þ
where Fj is the RR (compared to never smokers) rather than the
absolute risk. Note that while C has the same interpretation as it
has for prospective studies, the interpretation of B is different, being
the excess RR rather than the absolute risk for prospective studies.
Here there are more parameters to estimate. Apart from B and C,
estimates are also required of U1, U2 . . . Uk, the underlying frequen-
cies in the controls for groups 1 to k, with the frequency for never
smokers, U0, being estimated so that the sum of the frequencies
adds to 1. Based on the Uj, the relative frequencies of the cases
are given by UjFj, so that the actual frequencies of cases are given
by UjFj/z wherez ¼
Xk
j¼0
UjFj ð6Þ
The contribution to the log-likelihood of group j is given (again
ignoring terms that do not depend on the parameters) by
Qj ¼ log Lj ¼ Nj logUj þ nj logðUjFj=zÞ ð7Þ
Again, the overall log-likelihood for the block, L, was maximized
by Newton–Raphson methods, a sample of the estimates were con-
ﬁrmed using Excel, and formulae for estimation of the variance of
B, C and H were derived. Here the likelihood of the best-ﬁt model
can be obtained by substituting the observed values of the RRs for
Fj and the observed values of the frequencies of controls for Uj.
Available on request as Additional ﬁle 1: Fitting are the formulae
used for estimating the variance/covariance matrix of the log-like-
lihood functions with respect to the parameters A, B and C, and for
deriving the standard error (SE) of H and of log H from these esti-
mates. This ﬁle gives additional technical details on the procedures
used for maximizing the log-likelihood function.
2.5.4. Regression analyses
Sources of heterogeneity were studied by inverse–variance
weighted regression of log H. Between block variation in log H
was examined by study type, sex, continent, publication year,
mean age of the subjects studied, smoking category, smoking prod-
uct, current smoking RR, and numbers of cases in quitters both one
at a time, and using forward stepwise methods. The deviance of ﬁt-
ted models was used to indicate the extent to which the heteroge-
neity was explained. The estimates of log H and standard error of
log H from the ﬁxed effect models were then back transformed
to give estimates of H together with 95% conﬁdence limits. The
regression analyses were restricted to studies of populations with-
out speciﬁc diseases, the study of patients with human immunode-
ﬁciency virus (HIV) being reported separately.
2.5.5. Sensitivity analyses
Two alternative sensitivity analyses were conducted to study
how dependent estimates of H were on possible ‘‘reverse causa-
tion’’. In the ﬁrst of these analyses, RRs within a block which re-
lated to the earliest time of quitting were omitted. In the second,
all RRs within a block which related to a time of quitting of up to
2 years were considered to be current smokers, with the pseudo-
numbers for these RRs combined with those for the current smok-
ing RR. These are referred to as sensitivity analyses A and B.
Sensitivity analyses were also conducted to study the effect of
using alternative midpoint estimates for the ﬁnal, open-ended
above, quitting group. In the main analyses, the mean of the lower
limit and either 50 years or the upper limit of the age range studied
minus 20 years, if this was smaller than 50 years, was used. In the
alternative algorithms the value of 50 years was replaced by either
30 years (sensitivity analysis C) or 70 years (sensitivity analysis D)
in the calculation.
2.5.6. Software
All data entry and most statistical analyses were carried out
using ROELEE version 3.1 (available from P N Lee Statistics and
Computing Ltd., 17 Cedar Road, Sutton, Surrey SM2 5DA, UK). Some
analyses were conducted using Excel 2003.
3. Results
3.1. Studies identiﬁed
Thirty-ﬁve publications satisfying the inclusion and exclusion
criteria were identiﬁed from the searches carried out in November
Table 1
Literature searching; publications identiﬁed.
Source Result
IARC review (2007) 16 Publications identiﬁed (Ben-Shlomo et al., 1994; Bosetti et al., 1999; Burns et al., 1997; Cederlöf et al.,
1975; Cook et al., 1986; Dobson et al., 1991; Doll and Peto, 1976; Friedman et al., 1997; Hrubec and
McLaughlin, 1997; Iso et al., 2005; Kawachi et al., 1994; Negri et al., 1994; Rosenberg et al., 1985; Rosenberg
et al., 1990; US Surgeon General, 1990; Wen et al., 2005)
Lee review (2001) 7 new publications identiﬁed (Alderson et al., 1985; Alderson et al., 1986; Hammond and Horn, 1958;
Hirayama and Wahrendorf, 1990; Paganini-Hill and Hsu, 1994; Tang et al., 1992; Tverdal et al., 1993)
US Surgeon General Reviews, 1979, 1990, 2004 3 new publications identiﬁed (Doll and Hill, 1964; Hammond and Garﬁnkel, 1969; Kahn, 1966)
Company smoking and health ﬁles 8 new publications identiﬁed (Baba et al., 2006; Doll and Hill, 1956; Garﬁnkel and Stellman, 1988; Kenﬁeld
et al., 2008; Rogot and Murray, 1980; Tavani et al., 2001; Taylor et al., 2002; Teo et al., 2006)
Medline search in Sept 2009 for last 3 years 279 hits
1 new publication identiﬁed (Honjo et al., 2010)
Medline search in Oct 2011 for last 3 years 278 hits
1 new publication identiﬁed (Petoumenos et al., 2011)
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IARC review (2007) and only one from the ﬁrst PubMed search,Table 2
Selected details of the 23 studies.
Study REFa/Main Ref. b Location Sex Study
typec
Start
year(s)
ALDERS (Alderson et al., 1985)i England M + F CCH 1977–8
BOSETT (Bosetti et al., 1999)j Italy F CCH 1983–9
BRHS (Tang et al., 1992)l GB M P 1978–8
CEDERL (Cederlöf et al., 1975) Sweden Mm P 1963
CPSI (Hammond and Garﬁnkel, 1969)n USA Mm P 1959–6
CPSII (US Surgeon General, 1990)o USA M + F P 1982
DOBSON (Dobson et al., 1991) Australia M + F CCP 1988–8
DOLL (Doll and Peto, 1976)p GB Mm P 1951–5
HAMMON (Hammond and Horn, 1958) USA M P 1952
HIRAYA (Hirayama and Wahrendorf,
1990)
Japan M + F P 1965
HONJO (Honjo et al., 2010)q Japan M + F P 1983–9
HRUBEC (Kahn, 1966)r USA Ms P 1954–5
INTERH (Teo et al., 2006) 52
countries
M + F CCH 1995–0
KAISER (Friedman et al., 1997) USA M + F P 1979–8
NEGRI (Negri et al., 1994) Italy M + F CCH 1988–8
NURSES (Kenﬁeld et al., 2008)t USA F P 1976–0
PAGANI (Paganini-Hill and Hsu, 1994) USA M + F P 1981–8
ROSENF (Rosenberg et al., 1990) USA F CCH 1985–8
ROSENM (Rosenberg et al., 1985) USA M CCH 1980–8
TAVANI (Tavani et al., 2001) Italy M + F CCH 1995–9
TVERDA (Tverdal et al., 1993) Norway Mm P 1972–7
WEN (Wen et al., 2005) Taiwan M P 1989–9
WHITEH (Ben-Shlomo et al., 1994) England M P 1967–6
a Six character reference code used for study.
b Additional references giving results by time of quit are indicated against the speciﬁ
c CCH = case-control study with hospital controls, CCP = case-control study with popu
d Range of years when the case-control study was conducted or the baseline period f
e Only applicable to prospective studies. Relates to the longest period for which any
shorter period – CPSI 6 years and HRUBEC 8 years.
f AMI = acute myocardial infarction, CAD = coronary artery disease, CHD = coronary h
g B = both fatal and non-fatal cases, F = fatal cases, NF = non-fatal cases.
h Abbreviations used: ACS = American Cancer Society, GISSI-2 = Gruppo Italiano per
MONICA = Monitoring of Cardiovascular Disease.
i Additional reference (Alderson et al., 1986).
j Additional reference (Negri et al., 1994).
k Including study NEGRI.
l Additional reference (Cook et al., 1986).
m Study includes both sexes but the ex smoker results available for analysis are for m
n Additional reference (Burns et al., 1997).
o Additional references (Garﬁnkel and Stellman, 1988; Taylor et al., 2002).
p Additional references (Doll and Hill, 1956, 1964).
q Additional references (Baba et al., 2006; Iso et al., 2005).
r Additional references (Hrubec and McLaughlin, 1997; Rogot and Murray, 1980).
s Includes less than 0.5% women.
t Additional reference (Kawachi et al., 1994).which produced 279 hits. One publication (Hammond and Horn,
1958), which reported results for coronary artery disease (CAD)d
Follow-up
yearse
Outcomef Fatalityg Commentsh
2 – IHD NF 46 hospitals in 10 regions
2 – AMI NF Combined results from 2
studiesk
0 9 IHD B British Regional Heart Study
9 IHD F Probability sample, national
0 6 CHD F ACS 25 state study
12 CHD F ACS 50 state study
9 – IHD B WHO MONICA
2 20 IHD F Doctors
4 CAD F ACS 9 state study
17 IHD F Six prefectures
0 10 CHD F Pooled analysis of 3 studies
7 26 CHD F War veterans
3 – AMI NF INTERHEART
6 6 CHD F Kaiser Permanente, California
9 – AMI NF GISSI-2
4 24 CHD B Nurses’ Health Study
5 10 CHD F Retirement Community in LA
8 – AMI NF 71 hospitals in 4 states
3 – AMI NF 78 hospitals in 4 states
9 – AMI NF Milan
8 13 CHD F 5 regions
2 11 IHD F Government employees,
teachers
9 18 CHD F Civil servants
c studies.
lation controls, P = prospective study.
or prospective studies.
publication reported results. In two studies the results used in analysis were for a
eart disease, IHD = ischaemic heart disease.
lo Studio della Sopravvivenza nell’infarto Miocardico-study 2, LA = Los Angeles,
en only.
Table 3
Details of the 41 blocks used in analysis.
Blocka Study Ref.b Sex Age Exposurec Adjustedd Current smoker RR Cases in quitterse Quitting groups (years)f
1 ALDERS M 35–54 Cigarettes
only
Age 1.79 67.8 63, >3–10, >10g
2 55–74 0.73 97.8
3 F 35–54 2.44 64.8
4 55–74 1.67 113.8
5 BOSETT F 17–74 Cigarettes Age + 10 4.10 23.1 1–<5, 5+h
6 BRHS M 40–59 Cigarettes Age + 2 2.13 90.7 1–2, 3–5, 6–10, 11–20, 21+
7 CEDERL M 40–49 Any product Age 2.40 9.7 <10, 10+
8 50–59 1.70 52.3
9 60–69 1.40 125.6
10 CPSI M 40–79 Cigarettes
only 1–19/day
Age 1.90 264.7 <1, 1–4, 5–9, 10–19, 20+
11 20+/day 2.55 559.9
12 CPSII M 30+ Cigarettes
<21/day
Age 1.93 637.4 <1, 1–2, 3–5, 6–10, 11–15, 16+
13 21+/day 2.02 406.4
14 F 30+ Cigarettes
<20/day
1.76 120.9
15 20+/day 2.27 101.3
16 DOBSON M 35–69 Cigarettes Age + 1 2.71 224.4 <6 mo, 6–<12 mo, 1–3, 4–6, 7–
9, 10–12,>12
17 F 4.70 49.8
18 DOLL M 30–54 Cigarettes
only
Age 3.45 33.5 <5, 5–9, 10–14, 15+
19 55–64 1.69 134.8
20 65+ 1.30 312.1
21 HAMMON M 50–69 Cigarettes
only <20/day
Age 1.75 157.1 <1, 1- < 10, 10+
22 20+/day 2.20 122.7
23 HIRAYA M 40+ Any product Age 1.73 61.1 1–4, 5–9, 10+
24 F 1.90 2.2
25 HONJO M 40–79 Unspeciﬁed Age + 1 2.22 251.1 <2, 2–4, 5–9, 10–14, 15+
26 F 2.86 25.7
27 HRUBEC M 55–64 Cigarettes Age 1.67 920.3 1–4, 5–9, 10–14, 15+
28 65–74 1.54 1111.2
29 INTERH M+F 33–81 Any product Age,
sex + 5
3.04 1836.4 >1–3, >3–5, >5–10, >10–15,
>15–20, >20i
30 KAISER M 35+ Cigarettes
only
Age 1.79 101.6 2–10, 11–20, >20j
31 F 1.79 36.7
32 NEGRI M + F 24–74 Any product Age,
sex + 7
2.90 146.1 1, 2–5, 6–10, 11+h
33 NURSES F 30–55 Cigarettes Age 3.33 383.8 <5, 5–<10, 10–<15, 15–<20,
20+
34 PAGANI M 60–95 Cigarettes Age 1.41 391.7 65, 6–10, 11–20, >20
35 F 1.47 170.4
36 ROSENF F 25–64 Cigarettes Age 3.60 142.0 1–3 mo, 4–6 mo, 7–11 mo, 1–
<2, 2–<3, 3–5, 6–9, 10+
37 ROSENM M 20–54 Cigarettes Age 2.90 282.2 1–<2, 2–<3, 3–4, 5–9, 10–14,
15–19, 20+i
38 TAVANI M + F 25–79 Any product Age,
sex + 10
2.20 96.5 1–4, 5–9, 10+h
39 TVERDA M 35–49 Cigarettes Age + 1 4.20 195.8 <3 mo, 3–12 mo, 1–5, 5+
40 WEN M 35–64 Unspeciﬁed Age 2.50 19.3 0–5, 6–16, 17+k
41 WHITEH M 40–69 Cigarettes Age + 1 1.74 338.2 1–9, 10–19, 20–29, 30+
a Where there is no entry in a column for a block, the value is that given in the next completed row above.
b The data are generally from the main reference shown in Table 2. However, exceptions are noted below, as are details of data not used in the analysis, with reasons for
omission: ALDERS, The data from (Alderson et al., 1986) are the same as given in the main reference; BOSETT, Only the female data were used as the male data completely
overlap NEGRI. There is some overlap of the female data with the data for NEGRI; BRHS, The data from (Cook et al., 1986) were not used as they were based on a shorter
follow-up; CEDERL, The data for age group 40–69 years were omitted to avoid overlap; CPSI, The data used, from (Hammond and Garﬁnkel, 1969), are for 6 years follow-up.
The data from (Burns et al., 1997), though for 12 years follow-up, were not used as they were adjusted for smoking duration; CPS II, The data from (Garﬁnkel and Stellman,
1988) were omitted as being virtually the same as given in the main reference. The data from (Taylor et al., 2002) were omitted as the detail was inadequate; DOLL, The data
from (Doll and Hill, 1956, 1964) were not used as they were based on a shorter follow-up; HONJO, The data adjusted for smoking variables were not used. The data are
combined results from three studies. To avoid overlap, data from the individual studies (Baba et al., 2006; Iso et al., 2005) were not used; HRUBEC, The data used, from (Kahn,
1966), are for 8 years follow-up. The data from this source for smokers of cigarettes only were not used as data for cigarettes are more commonly available in other studies.
The data from (Hrubec and McLaughlin, 1997), though for 26 years follow-up were not used as there were no data for current smokers. The data from (Rogot and Murray,
1980), for 16 years follow-up, were not used as they were given graphically, and difﬁcult to use; NEGRI, See BOSETT; NURSES, The multivariate data including adjustment for
age of starting to smoke not used. The data from (Kawachi et al., 1994) were not used as they were based on shorter follow-up.
c ‘‘Cigarettes’’ = cigarettes ± other products (pipes and cigars), ‘‘Any product’’ = cigarettes and/or other products.
d Age + n (or Age, sex + n) indicates the number of other non smoking risk factors that were adjusted for: BOSETT, Education, study centre, cholesterol, diabetes, hyper-
tension, hyperlipidaemia, family history of AMI, coffee, alcohol, body mass index (BMI); BRHS, Blood pressure, cholesterol; DOBSON, History of AMI or other IHD; HONJO,
Cohort; INTERH, Region, exercise, fruit, vegetables, alcohol; NEGRI, Education, BMI, cholesterol, diabetes, hypertension, family history of AMI, coffee; TAVANI, Education, BMI,
cholesterol, coffee, alcohol, physical activity, hyperlipidaemia, diabetes, hypertension, family history of AMI; TVERDA, Area; WHITEH, Employment grade.
e Estimated pseudo-numbers by method of Hamling et al. (2008).
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f Based on time of interview for case-control and time of baseline interview for prospective studies, except that for prospective studies DOLL (blocks 18–20) and NURSES
(block 33) time of quit was updated at intervals based on repeat interviews. Exceptionally, in studies HRUBEC (blocks 27 and 28) and WHITEH (block 41), and possibly also in
study HONJO (blocks 25 and 26) the time of quit in subjects was recategorized during follow-up. Thus a subject reporting having quit for four years at baseline, would have
been counted as having quit for nine years, ﬁve years later.
g Subjects were asked whether they smoked 1, 3, 5 or 10 years before hospital admission, or at ages 16, 20 and 25 years.
h Only quitters of at least one year were considered to be ex smokers.
i Quitters for less than a year were included among the current smokers.
j Only quitters of at least two years were considered to be ex smokers.
k Only quitters of at least six months were considered to be ex smokers.
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IHD. The second PubMed search, in October 2011, produced 278
hits, but only two new relevant publications. One of these (Kondo
et al., 2011) described results involving only three AMI cases in
quitters, and was ignored. The other (Petoumenos et al., 2011) de-
scribes a study in HIV positive patients, and is considered
separately.
The 35 publications identiﬁed in 2009 were divided into 23
studies. Table 2 gives selected details of these studies, including
the study reference (REF), the main reference used as source for
the data considered, and the additional references to data not actu-
ally used for reasons discussed below under ‘‘blocks rejected’’. Note
that BOSETT and NEGRI have a small overlap inasmuch as they
both include data for females interviewed in 1988–1989 in the
GISSI-2 study. Note also that HONJO is based on a combined anal-
ysis of three studies. Results from two of these studies have been
reported separately (Baba et al., 2006; Iso et al., 2005), but their
data have not been included in our analyses, so as to avoid marked
overlap.
Of the 23 studies, nine were conducted in the USA, nine in Eur-
ope, and three in Asia, with one in Australia and one conducted in
52 countries. The results relate only to males in ten studies, only to
females in three, and to both sexes in ten. Fifteen were prospective
studies, with follow-up periods ranging from 4 to 26 years, seven
were case-control studies with hospital controls, and one was a
case-control study with population controls. Of the eight
case-control studies, six were of AMI and two of CHD, with only
one including any fatal cases. Of the 15 prospective studies, all
were of IHD, CHD or CAD, and only two included any nonfatal
cases. Four of the studies started in the 1950s, three in the
1960s, ﬁve in the 1970s, nine in the 1980s and two in the 1990s.
Although some studies related to speciﬁc populations, such as doc-
tors, nurses or war veterans, none related to populations with spe-
ciﬁc medical conditions.
3.2. Blocks considered in the analysis
Table 3 gives some details of the 41 blocks considered in anal-
ysis. Of the 23 studies, 11 provided only a single block (ﬁve for
males, three for females and three for sexes combined), ﬁve pro-
vided results only by sex, three only by age, and two only by level
of consumption. One study provided blocks jointly by age and sex,
and one jointly by sex and level of consumption. Seventeen of the
blocks related to smoking of cigarettes, regardless of pipes and ci-
gars, 13 to smoking of cigarettes only, eight to smoking of any
product, and three to unspeciﬁed smoking. The RRs were adjusted
for age in all 41 blocks, and for additional non-smoking variables
(see footnote d of Table 3 for details) in 11 blocks, from nine
studies. Numbers of cases in quitters (estimated from the pseu-
do-tables) ranged from less than 10 in block 7 (CEDERL, age
40–49 years) and block 24 (HIRAYA, females) to over 1000 in block
28 (HRUBEC, age 65–74 years) and block 29 (INTERH), with a med-
ian of 130.2. Current smoking RRs were, with one exception (block
2, ALDERS, males, age 55–74 years) above 1.0 in all blocks, exceed-
ing 2.0 in 21 blocks, and 4.0 in three of these, the largest being the
RR of 4.70 in block 17 (DOBSON, females).Numbers of quitting groups ranged from two to eight, most
commonly being three (12 blocks) or four (10 blocks). Generally
quitting periods were as reported at time of interview in case-con-
trol studies, or as at baseline in prospective studies, with no updat-
ing of the time as follow-up progressed. However, in the
prospective studies DOLL (blocks 18–20) and NURSES (block 33)
time of quit was updated at intervals based on the latest informa-
tion recorded in repeat interviews, with RRs related to the most re-
cent quitting period reported. Also, time of quit was updated
during follow-up in studies HRUBEC (blocks 27 and 28) and
WHITEH (block 41), and may also have been updated in study
HONJO (blocks 25 and 26). In most studies, length of time quit
did not affect the deﬁnition of an ex smoker. However, quitters
of less than a year were reclassiﬁed as current smokers in studies
INTERH (block 29) and ROSENM (block 37). Also, WEN (block 40)
excluded quitters of less than six months, BOSETT (block 5), NEGRI
(block 32) and TAVANI (block 38) excluded quitters of less than a
year, and KAISER (blocks 30 and 31) excluded quitters of less than
two years, although none of these studies appeared to include the
excluded ex smokers within the current smoking group.
3.3. Blocks rejected
As detailed further in footnote b to Table 3, some available data
sets were not included in the main analysis. The reasons for this in-
clude avoidance of data from earlier follow-ups, when adequate
data from a later follow-up were available, avoidance where possi-
ble of overlap between blocks, and avoidance of data sets where
the only available RRs for quitters were relative to current smokers,
and adjusted for other smoking variables, such as amount smoked,
duration of smoking, or age of starting to smoke, since one cannot
similarly adjust RRs for never smokers relative to current smokers.
This last reason meant that, for study CPS I, data from a six year fol-
low-up (Hammond and Garﬁnkel, 1969) rather than a 12 year fol-
low-up (Burns et al., 1997) were used, and that, for study HRUBEC,
data from an eight year follow-up (Kahn, 1966) rather than a
26 year follow-up (Hrubec and McLaughlin, 1997) were used.
3.4. Fitting the negative exponential model
Table 4 shows, for each of the 41 blocks, the data used for ﬁtting
the negative exponential model, including, for each smoking group,
the complete set of RRs and CIs (expressed relative to never smok-
ers), the pseudo-numbers of cases corresponding to these RRs
(‘‘cases observed’’), and the value of the mean years quit assumed
for each level of quitting. Table 4 also gives the results of ﬁtting the
negative exponential model to each of the blocks separately, show-
ing the ﬁtted RR values (again relative to never smokers), the ﬁtted
numbers of cases, the estimates of H and its SE, as well as the chis-
quared value, v2(ﬁt), degrees of freedom (DF), and the correspond-
ing p value for goodness-of-ﬁt. Available on request are two
additional ﬁles. Additional ﬁle 2: Estimates gives further details
of the ﬁt, including the ﬁtted values of the parameters A and B,
and the full variance/covariance matrix of the estimates. Additional
ﬁle 3: Plots presents a ﬁgure for each block, showing the goodness-
of-ﬁt of the negative exponential model.
Table 4
Fit of the negative exponential model to the data for the 41 blocks.
Block: studya Sexb Agec Smoking group Years quit RR (95% CI)d Fitted RR Cases observede Cases ﬁttedf
1: ALDERS M 35–54 Current 1.79 (1.12–2.85) 1.99 95.96 99.51
Ex 1.50 2.27 (1.25–4.10) 1.81 40.78 36.03
H = 5.18 Ex 6.50 1.21 (0.56–2.61) 1.42 14.33 15.37
SE(H) = 4.67 Ex 22.00 0.89 (0.41–1.92) 1.05 12.72 13.85
v2(ﬁt) = 1.79 (6 DF) p = 0.94 Never 1.00 1.00 43.16 42.20
2: ALDERS M 55–74 Current 0.73 (0.44–1.20) 0.69 68.60 68.60
Ex 1.50 1.31 (0.67–2.59) 1.00 29.74 27.07
H = 0.03 Ex 6.50 0.83 (0.40–1.73) 1.00 18.87 21.36
SE(H) = 728690 Ex 30.00 1.13 (0.64–2.00) 1.00 49.21 47.83
v2(ﬁt) = 1.35 (6 DF) p = 0.97 Never 1.00 1.00 51.86 53.43
3: ALDERS F 35–54 Current 2.44 (1.67–3.57) 2.44 164.55 164.56
Ex 1.50 2.05 (1.19–3.53) 2.05 40.51 40.50
H = 3.29 Ex 6.50 1.37 (0.66–2.81) 1.37 16.07 16.05
SE(H) = 2.76 Ex 22.00 1.00 (0.40–2.48) 1.01 8.26 8.32
v2(ﬁt) = 0.0001 (6 DF) p = 1.00 Never 1.00 1.00 68.71 68.65
4: ALDERS F 55–74 Current 1.67 (1.17–2.37) 1.63 120.89 119.08
Ex 1.50 1.22 (0.74–2.01) 1.44 38.14 41.11
H = 2.98 Ex 6.50 1.23 (0.75–2.03) 1.14 39.11 37.34
SE(H) = 4.85 Ex 30.00 0.92 (0.57–1.49) 1.00 36.53 38.09
v2(ﬁt) = 0.83 (6 DF) p = 0.99 Never 1.00 1.00 147.95 146.99
5: BOSETT F 17–74 Current 4.10 (2.30–5.70) 3.99 64.90 64.23
H = 7.61 Ex 3.00 2.90 (1.30–6.70) 3.28 12.15 12.95
SE(H) = 6.16 Ex 27.50 1.30 (0.60–2.70) 1.24 10.91 10.60
v2(ﬁt) = 0.13 (5 DF) p = 1.00 Never 1.00 1.00 70.44 70.61
6: BRHS M 40–59 Current 2.13 (1.59–2.86) 2.14 198.95 199.30
Ex 2.00 1.80 (1.01–3.19) 1.74 13.53 13.01
Ex 4.50 1.52 (0.90–2.56) 1.43 17.55 16.42
Ex 8.50 0.98 (0.58–1.67) 1.18 17.44 20.90
H = 3.17 Ex 16.50 1.26 (0.80–1.97) 1.03 27.04 22.14
SE(H) = 1.99 Ex 30.00 0.84 (0.48–1.47) 1.00 15.14 18.01
v2(ﬁt) = 2.31 (3 DF) p = 0.51 Never 1.00 1.00 53.57 53.43
7: CEDERL M 40–49 Current 2.40 (0.92–6.23) 2.70 25.99 28.88
H = 22.12 Ex 5.00 4.40 (1.49–13.04) 2.46 9.19 5.06
SE(H) = 42.05 Ex 19.50 0.53 (0.03–9.57) 1.92 0.51 1.82
v2(ﬁt) = 4.40 (3 DF) p = 0.22 Never 1.00 1.00 4.97 4.90
8: CEDERL M 50–59 Current 1.70 (1.28–2.26) 1.78 212.05 215.68
H = 9.03 Ex 5.00 1.80 (1.19–2.73) 1.53 33.39 27.59
SE(H) = 5.90 Ex 24.50 0.90 (0.54–1.50) 1.12 18.94 22.85
v2(ﬁt) = 2.05 (3 DF) p = 0.56 Never 1.00 1.00 58.55 56.80
9: CEDERL M 60–69 Current 1.40 (1.17–1.67) 1.40 348.61 348.24
H = 14.29 Ex 5.00 1.30 (0.98–1.73) 1.31 57.49 58.05
SE(H) = 13.98 Ex 29.50 1.10 (0.84–1.44) 1.10 68.15 67.88
v2(ﬁt) = 0.01 (3 DF) p = 1.00 Never 1.00 1.00 157.64 157.74
10: CPSI M 40–79 Current 1.90 (1.76–2.05) 1.89 1011.95 1008.66
(1–19/day) Ex 0.50 1.62 (1.13–2.33) 1.74 29.13 31.47
Ex 3.00 1.22 (0.94–1.58) 1.31 57.79 62.26
Ex 7.50 1.26 (0.97–1.64) 1.06 56.44 47.83
H = 1.97 Ex 15.00 0.96 (0.73–1.26) 1.00 52.35 55.01
SE(H) = 1.15 Ex 35.00 1.08 (0.85–1.37) 1.00 68.96 64.11
v2(ﬁt) = 2.54 (3 DF) p = 0.47 Never 1.00 1.00 1781.91 1789.19
11: CPSI M 40–79 Current 2.55 (2.41–2.70) 2.49 2971.01 2949.90
(20+/day) Ex 0.50 1.61 (1.25–2.07) 2.23 60.89 85.77
Ex 3.00 1.51 (1.28–1.78) 1.47 149.11 147.83
Ex 7.50 1.16 (0.98–1.38) 1.08 138.32 131.43
H = 1.81 Ex 15.00 1.25 (1.05–1.49) 1.00 131.71 107.60
SE(H) = 0.42 Ex 35.00 1.05 (0.84–1.31) 1.00 79.84 77.28
v2(ﬁt) = 14.53 (3 DF) p = 0.002 Never 1.00 1.00 1909.99 1941.10
12: CPSII M 30+ Current 1.93 (1.74–2.14) 2.00 607.94 605.76
(<21/day) Ex 0.50 1.43 (0.84–2.42) 1.92 13.80 17.81
Ex 2.00 1.61 (1.21–2.15) 1.71 48.59 49.70
Ex 4.50 1.49 (1.11–2.00) 1.47 46.24 43.76
Ex 8.50 1.28 (1.03–1.59) 1.24 89.23 82.89
H = 4.10 Ex 13.50 0.99 (0.80–1.23) 1.10 91.28 97.60
SE(H) = 1.01 Ex 33.00 0.88 (0.78–1.00) 1.00 348.27 381.54
v2(ﬁt) = 6.45 (3 DF) p = 0.09 Never 1.00 1.00 852.64 818.92
13: CPSII M 30+ Current 2.02 (1.82–2.25) 2.00 575.88 573.98
(21+/day) Ex 0.50 2.56 (1.63–4.04) 1.95 18.85 14.45
Ex 2.00 1.57 (1.11–2.22) 1.81 32.91 38.27
Ex 4.50 1.41 (1.01–1.97) 1.63 35.58 41.37
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Table 4 (continued)
Block: studya Sexb Agec Smoking group Years quit RR (95% CI)d Fitted RR Cases observede Cases ﬁttedf
Ex 8.50 1.63 (1.27–2.09) 1.42 66.20 57.90
H = 6.71 Ex 13.50 1.16 (0.91–1.48) 1.25 69.96 75.81
SE(H) = 2.25 Ex 33.00 1.09 (0.93–1.28) 1.03 182.94 174.64
v2(ﬁt) = 4.95 (3 DF) p = 0.17 Never 1.00 1.00 817.09 823.00
14: CPSII F 30+ Current 1.76 (1.33–2.33) 1.74 55.34 55.82
(<20/day) Ex 0.50 2.13 (0.68–6.64) 1.38 2.97 1.97
Ex 2.00 0.87 (0.41–1.84) 1.05 6.93 8.54
Ex 4.50 1.31 (0.72–2.39) 1.00 10.94 8.54
Ex 8.50 0.74 (0.41–1.32) 1.00 11.55 15.93
H = 0.52 Ex 13.50 1.20 (0.73–1.96) 1.00 16.36 13.92
SE(H) = 0.74 Ex 33.00 1.17 (0.91–1.50) 1.00 72.20 62.99
v2(ﬁt) = 4.60 (3 DF) p = 0.20 Never 1.00 1.00 412.77 421.36
15: CPSII F 30+ Current 2.27 (1.83–2.82) 2.18 106.38 106.32
(20+/day) Ex 0.50 1.41 (0.73–2.74) 1.38 8.99 9.15
Ex 2.00 1.16 (0.62–2.18) 1.01 9.98 9.07
Ex 4.50 0.96 (0.58–1.59) 1.00 15.76 17.10
Ex 8.50 1.88 (1.24–2.86) 1.00 23.40 12.97
H = 0.30 Ex 13.50 1.37 (0.77–2.44) 1.00 11.92 9.06
SE(H) = 0.36 Ex 33.00 1.12 (0.78–1.62) 1.00 31.24 29.06
v2(ﬁt) = 8.56 (3 DF) p = 0.04 Never 1.00 1.00 358.21 373.15
16: DOBSON M 35–69 Current 2.71 (2.07–3.53) 2.79 304.57 307.68
Ex 0.25 4.31 (1.89–9.85) 2.66 20.47 17.28
Ex 0.75 2.38 (0.91–6.20) 2.41 10.19 10.22
Ex 2.50 1.95 (1.15–3.20) 1.81 36.18 34.80
Ex 5.50 1.02 (0.60–1.74) 1.31 24.76 28.75
Ex 8.50 1.40 (0.77–2.53) 1.12 21.83 19.08
H = 2.17 Ex 11.50 1.13 (0.67–1.89) 1.05 27.37 26.01
SE(H) = 1.01 Ex 31.00 0.96 (0.69–1.34) 1.00 83.60 85.59
v2(ﬁt) = 3.50 (10 DF) p = 0.97 Never 1.00 1.00 152.19 151.75
17: DOBSON F 35–69 Current 4.70 (3.35–6.58) 4.86 112.17 112.35
Ex 0.25 3.24 (1.15–9.19) 4.58 6.51 7.69
Ex 0.75 9.97 (2.11–47.07) 4.08 5.40 3.71
Ex 2.50 2.86 (1.23–6.66) 2.82 9.55 9.30
Ex 5.50 1.29 (0.49–3.37) 1.74 5.63 6.87
Ex 8.50 1.26 (0.49–3.21) 1.30 5.91 5.91
H = 2.30 Ex 11.50 1.71 (0.59–4.94) 1.12 4.95 3.51
SE(H) = 1.11 Ex 31.00 0.71 (0.37–1.35) 1.00 11.89 15.44
v2(ﬁt) = 4.06 (10 DF) p = 0.94 Never 1.00 1.00 112.76 109.99
18: DOLL M 30–54 Current 3.45 (2.29–5.19) 3.04 73.02 72.91
Ex 2.50 1.86 (0.83–4.19) 1.69 6.97 7.18
Ex 7.50 1.21 (0.59–2.46) 1.08 9.76 9.91
H = 1.60 Ex 12.50 1.55 (0.76–3.16) 1.01 9.72 7.17
SE(H) = 1.47 Ex 24.50 1.62 (0.72–3.63) 1.00 7.08 4.95
v2(ﬁt) = 2.19 (3 DF) p = 0.53 Never 1.00 1.00 33.08 37.51
19: DOLL M 55–64 Current 1.69 (1.32–2.18) 1.71 236.21 237.93
Ex 2.50 1.88 (1.15–3.08) 1.66 18.78 16.55
Ex 7.50 1.41 (0.95–2.09) 1.57 33.44 37.35
H = 24.43 Ex 12.50 1.73 (1.18–2.53) 1.50 37.59 32.52
SE(H) = 16.88 Ex 29.50 1.25 (0.87–1.80) 1.31 45.02 46.85
v2(ﬁt) = 1.62 (3 DF) p = 0.66 Never 1.00 1.00 78.73 78.57
20: DOLL M 65+ Current 1.30 (1.09–1.55) 1.29 325.00 322.10
Ex 2.50 0.99 (0.65–1.49) 1.26 23.92 30.54
Ex 7.50 1.32 (1.02–1.72) 1.21 73.46 67.26
H = 17.41 Ex 12.50 1.13 (0.86–1.49) 1.17 62.27 64.72
SE(H) = 15.27 Ex 32.50 1.08 (0.88–1.33) 1.08 152.40 152.48
v2(ﬁt) = 2.40 (3 DF) p = 0.49 Never 1.00 1.00 186.93 186.88
21: HAMMON M 50–69 Current 1.75 (1.59–1.92) 1.76 1072.45 1076.72
(<20/day) Ex 0.50 2.09 (1.38–3.16) 1.73 22.83 18.92
H = 10.42 Ex 5.50 1.54 (1.22–1.94) 1.53 78.61 77.84
SE(H) = 5.74 Ex 29.50 1.09 (0.83–1.43) 1.11 55.62 56.43
v2(ﬁt) = 0.85 (3 DF) p = 0.84 Never 1.00 1.00 714.59 714.19
22: HAMMON M 50–69 Current 2.20 (1.97–2.45) 2.22 591.86 596.38
(20+/day) Ex 0.50 3.00 (1.89–4.77) 2.20 18.09 13.28
H = 29.08 Ex 5.50 2.06 (1.60–2.66) 2.07 64.22 64.44
SE(H) = 16.94 Ex 29.50 1.60 (1.17–2.20) 1.60 40.41 40.47
v2(ﬁt) = 1.62 (3 DF) p = 0.65 Never 1.00 1.00 697.33 697.32
23: HIRAYA M 40+ Current 1.73 (1.52–1.97) 1.74 1740.60 1740.96
Ex 3.00 1.50 (1.02–2.20) 1.60 28.38 30.20
H = 10.29 Ex 7.00 1.73 (1.10–2.72) 1.44 19.80 16.47
SE(H) = 8.21 Ex 30.00 0.94 (0.54–1.64) 1.10 12.93 15.05
v2(ﬁt) = 1.08 (2 DF) p = 0.78 Never 1.00 1.00 259.29 258.33
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Block: studya Sexb Agec Smoking group Years quit RR (95% CI)d Fitted RR Cases observede Cases ﬁttedf
24: HIRAYA F 40+ Current 1.90 (1.66–2.17) 1.90 259.10 259.10
Ex 2.50 0.41 (0.05–3.37) g – – –
H = 3.30 Ex 7.00 1.19 (0.20–6.94) 1.19 1.21 1.21
SE(H) = 11.70 Ex 30.00 0.91 (0.12–6.74) 1.00 0.94 1.03
v2(ﬁt) = 0.01 (3 DF) p = 1.00 Never 1.00 1.00 1131.46 1131.37
25: HONJO M 40–79 Current 2.22 (1.82–2.71) 2.33 737.51 749.54
Ex 1.00 1.62 (0.93–2.82) 2.26 14.09 19.02
Ex 3.50 2.44 (1.78–3.35) 2.10 58.01 48.25
Ex 7.50 2.36 (1.77–3.14) 1.88 79.93 61.87
H = 12.62 Ex 12.50 1.40 (0.98–2.01) 1.67 39.65 45.83
SE(H) = 3.41 Ex 32.50 1.04 (0.76–1.43) 1.22 59.45 67.50
v2(ﬁt) = 10.33 (3 DF) p = 0.02 Never 1.00 1.00 112.15 108.77
26: HONJO F 40–79 Current 2.86 (2.25–3.62) 3.10 85.52 92.35
Ex 1.00 5.11 (1.91–13.69) 2.95 3.96 2.28
Ex 3.50 6.31 (3.46–11.53) 2.64 10.77 4.58
Ex 7.50 2.63 (1.25–5.52) 2.24 7.09 6.01
H = 9.84 Ex 12.50 1.09 (0.26–4.45) 1.87 1.93 3.32
SE(H) = 5.45 Ex 32.50 0.60 (0.15–2.45) 1.21 1.95 3.94
v2(ﬁt) = 10.01 (3 DF) p = 0.02 Never 1.00 1.00 327.58 326.44
27: HRUBEC M 55–64 Current 1.67 (1.56–1.78) 1.68 3100.09 3098.60
Ex 3.00 1.35 (1.14–1.59) 1.51 156.66 173.84
Ex 7.50 1.48 (1.30–1.69) 1.33 268.18 238.85
H = 7.28 Ex 12.50 1.13 (0.96–1.34) 1.21 155.00 163.55
SE(H) = 1.61 Ex 29.50 0.98 (0.87–1.11) 1.04 340.48 357.00
v2(ﬁt) = 6.61 (3 DF) p = 0.09 Never 1.00 1.00 1182.65 1171.20
28: HRUBEC F 55–64 Current 1.54 (1.45–1.64) 1.53 2856.97 2841.20
Ex 3.00 1.02 (0.78–1.32) 1.47 56.86 82.19
Ex 7.50 1.37 (1.21–1.55) 1.39 309.43 313.66
H = 16.69 Ex 12.50 1.42 (1.24–1.61) 1.32 265.27 246.47
SE(H) = 4.17 Ex 29.50 1.12 (1.02–1.24) 1.14 479.63 485.55
v2(ﬁt) = 10.51 (3 DF) p = 0.01 Never 1.00 1.00 1540.22 1539.42
29: INTERH M 33–81 Current 3.04 (2.85–3.25) 2.85 4338.79 4293.21
Ex 2.00 1.87 (1.55–2.24) 2.38 238.99 272.30
Ex 4.00 1.57 (1.25–1.97) 2.03 141.07 163.87
Ex 7.50 1.51 (1.29–1.76) 1.61 311.64 329.80
Ex 12.50 1.45 (1.25–1.69) 1.29 326.70 312.69
H = 4.71 Ex 17.50 1.55 (1.30–1.84) 1.14 247.64 211.70
SE(H) = 0.83 Ex 35.00 1.22 (1.09–1.37) 1.01 570.39 519.08
v2(ﬁt) = 40.38 (9 DF) p < 0.001 Never 1.00 1.00 2915.16 2987.74
30: KAISER M 35+ Current 1.79 (1.39–2.31) 1.79 109.22 108.46
Ex 6.50 1.30 (0.80–2.12) 1.47 18.42 20.71
H = 8.72 Ex 16.00 1.30 (0.91–1.85) 1.22 39.75 37.12
SE(H) = 5.58 Ex 35.50 1.00 (0.71–1.41) 1.05 43.46 45.25
v2(ﬁt) = 0.53 (3 DF) p = 0.91 Never 1.00 1.00 130.17 129.48
31: KAISER F 35+ Current 1.79 (1.29–2.50) 1.78 57.63 57.21
Ex 6.50 1.40 (0.71–2.75) 1.55 9.23 10.22
H = 12.72 Ex 16.00 1.40 (0.81–2.43) 1.33 14.82 14.08
SE(H) = 12.82 Ex 35.50 1.10 (0.61–1.98) 1.12 12.64 12.82
v2(ﬁt) = 0.15 (3 DF) p = 0.99 Never 1.00 1.00 89.50 89.49
32: NEGRI M + F 24–74 Current 2.90 (2.20–3.90) 2.75 363.24 362.23
Ex 1.50 1.60 (0.80–3.20) 1.89 15.81 17.79
Ex 4.00 1.40 (0.90–2.10) 1.29 51.78 50.76
H = 1.55 Ex 8.50 1.20 (0.70–2.10) 1.04 24.44 22.95
SE(H) = 0.77 Ex 30.50 1.10 (0.80–1.80) 1.00 54.08 52.39
v2(ﬁt) = 0.85 (7 DF) p = 1.00 Never 1.00 1.00 98.37 101.61
33: NURSES F 30–55 Current 3.33 (2.91–3.81) 3.37 525.98 522.80
Ex 2.50 1.67 (1.31–2.12) 1.84 80.09 86.93
Ex 7.50 1.23 (0.94–1.62) 1.11 58.77 51.74
Ex 12.50 1.33 (1.01–1.75) 1.01 59.42 44.34
H = 1.67 Ex 17.50 1.20 (0.91–1.58) 1.00 58.77 48.16
SE(H) = 0.50 Ex 27.50 0.77 (0.63–0.94) 1.00 126.75 162.33
v2(ﬁt) = 16.86 (3 DF) p = 0.001 Never 1.00 1.00 358.94 352.41
34: PAGANI M 60–95 Current 1.41 (1.03–1.93) 1.68 47.15 55.25
Ex 3.00 2.02 (1.44–2.84) 1.56 38.61 29.34
Ex 8.50 1.43 (1.02–1.99) 1.39 40.49 38.82
H = 10.75 Ex 16.00 1.21 (0.96–1.53) 1.24 106.35 107.50
SE(H) = 4.55 Ex 35.50 1.03 (0.85–1.25) 1.07 206.26 210.87
v2(ﬁt) = 4.24 (3 DF) p = 0.24 Never 1.00 1.00 200.72 197.81
35: PAGANI F 60–95 Current 1.47 (1.10–1.95) 1.50 58.92 60.05
Ex 3.00 1.28 (0.81–2.01) 1.46 20.15 22.93
(continued on next page)
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Table 4 (continued)
Block: studya Sexb Agec Smoking group Years quit RR (95% CI)d Fitted RR Cases observede Cases ﬁttedf
Ex 8.50 1.42 (0.93–2.15) 1.39 24.07 23.54
H = 23.92 Ex 16.00 1.53 (1.14–2.04) 1.32 56.53 48.47
SE(H) = 17.08 Ex 35.50 1.09 (0.83–1.42) 1.18 69.68 75.16
v2(ﬁt) = 2.08 (3 DF) p = 0.56 Never 1.00 1.00 220.74 219.96
36: ROSENF F 25–64 Current 3.60 (3.00–4.40) 3.61 588.20 589.04
Ex 0.167 3.00 (1.50–5.80) 3.29 13.97 14.79
Ex 0.375 3.60 (1.80–7.20) 2.94 14.22 12.54
Ex 0.75 2.30 (0.90–5.90) 2.45 6.43 6.70
Ex 1.50 2.00 (1.10–3.70) 1.80 15.49 14.32
Ex 2.50 1.30 (0.70–2.60) 1.36 11.83 12.28
Ex 4.50 0.80 (0.40–1.80) 1.08 8.20 10.53
H = 0.88 Ex 8.00 1.10 (0.70–1.80) 1.00 23.53 21.80
SE(H) = 0.31 Ex 27.00 1.00 (0.70–1.40) 1.00 48.40 48.54
v2(ﬁt) = 1.40 (11 DF) p = 1.00 Never 1.00 1.00 177.96 177.83
37: ROSENM M 25–64 Current 2.90 (2.40–3.40) 2.81 1365.48 1365.95
Ex 1.50 2.00 (1.10–3.80) 1.55 18.00 15.72
Ex 2.50 1.10 (0.60–1.90) 1.25 17.20 19.31
Ex 4.00 1.00 (0.60–1.60) 1.08 23.89 25.87
Ex 7.50 1.40 (1.10–2.00) 1.00 59.56 48.25
Ex 12.50 1.00 (0.70–1.40) 1.00 54.05 55.43
H = 0.88 Ex 17.50 1.30 (0.90–1.80) 1.00 58.18 49.40
SE(H) = 0.41 Ex 27.00 0.80 (0.60–1.20) 1.00 51.29 62.40
v2(ﬁt) = 9.55 (10 DF) p = 0.48 Never 1.00 1.00 208.51 213.83
38: TAVANI M + F 25–79 Current 2.20 (1.50–3.10) 2.56 149.30 150.22
Ex 3.00 2.00 (0.90–4.00) 1.87 21.10 19.51
H = 3.54 Ex 7.50 1.10 (0.50–2.50) 1.36 12.74 13.25
SE(H) = 2.12 Ex 30.00 0.70 (0.50–1.10) 1.00 62.64 71.74
v2(ﬁt) = 3.63 (6 DF) p = 0.73 Never 1.00 1.00 126.89 117.95
39: TVERDA M 35–49 Current 4.20 (3.37–5.23) 3.59 855.90 849.94
Ex 0.125 3.83 (2.44–6.02) 3.41 23.92 24.72
Ex 0.625 2.48 (1.58–3.90) 2.80 23.92 31.30
H = 1.18 Ex 3.00 1.77 (1.28–2.45) 1.44 62.32 59.05
SE(H) = 0.31 Ex 17.00 1.37 (1.02–1.85) 1.00 85.65 72.59
v2(ﬁt) = 6.42 (3 DF) p = 0.09 Never 1.00 1.00 87.60 101.70
40: WEN M 35–64 Current 2.50 (1.54–4.06) 2.36 42.98 42.99
Ex 3.25 1.55 (0.59–4.10) 1.45 4.79 4.77
H = 2.05 Ex 11.50 1.08 (0.46–2.50) 1.03 6.76 6.86
SE(H) = 2.67 Ex 30.50 1.35 (0.61–3.00) 1.00 7.80 6.13
v2(ﬁt) = 0.51 (3 DF) p = 0.92 Never 1.00 1.00 26.13 27.72
41: WHITEH M 40–69 Current 1.74 (1.49–2.04) 1.68 768.40 767.23
Ex 5.50 1.44 (1.03–2.03) 1.42 36.67 37.47
Ex 15.00 1.19 (0.94–1.50) 1.19 103.06 106.29
H = 8.01 Ex 25.00 1.13 (0.89–1.43) 1.08 98.85 97.65
SE(H) = 4.27 Ex 39.50 1.15 (0.91–1.46) 1.02 99.67 91.74
v2(ﬁt) = 1.10 (3 DF) p = 0.78 Never 1.00 1.00 177.20 183.49
1–41: TOTAL Current 27395.31 27340.93
Ex <2 517.07 535.63
Ex 2–<5 1583.17 1683.61
Ex 5–<10 2213.86 2124.71
Ex 10–<15 1240.20 1208.80
Ex 15–<20 982.36 881.88
Ex 20+ 3746.59 3805.24
Never 18136.34 18234.13
a For each block, the block number and study reference code is shown. Also shown in this column is the estimate of half-life, H, its SE, SE(H), and the chisquared value for ﬁt
of the model, v2(ﬁt), based on twice the difference in log-likelihood between the ﬁtted model, and the best-ﬁt model.
b Apart from the sex of the subjects considered in the block, the entries in the column also show the DF for v2(ﬁt).
c Apart from the age group of the subjects considered in the block, the entries in the column also show the level of consumption (for blocks 10–15, 21–22 only) and the
probability, p, value associated with v2(ﬁt) and its DF.
d These estimates were as provided in the original source, except where it has been necessary to calculate them from adjusted rates (blocks 7–9, 21–22, 27–28, 39) or from
adjusted observed/expected ratios (blocks 18–20), or to calculate 95% CI where only the RR was given (blocks 1–4). In some cases estimates were given in ﬁgures (blocks 6,
21–22, 36, 37). Where RRs and CIs were entered with a current smoker base (blocks 1–4, 18–20, 25–28, 33, 40) these have been recalculated with a never smoker base via the
pseudo-numbers.
e These are pseudo-numbers of cases deﬁned by the method of Hamling et al. (2008). Corresponding values for the controls and at risk population are available on request,
as are the ﬁtted values of the other parameters A and B.
f Corresponding values for the controls are available on request.
g RR not included in estimation as based on one death only.
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while there is in most cases no real indication of misﬁt, with the
p value 0.05 or more in 34 of the 41 blocks, there are some blocks
which deserve mention, considered in order of misﬁt. Block 29 (IN-TERH, p < 0.001) – The RR declines rapidly initially up to 4 years
quitting, but there is no evidence of further decline up to
17.5 years, and even after 35 years there is an excess RR compared
to never smokers of 1.22 (95% CI 1.09–1.37). Block 33 (NURSES,
P.N. Lee et al. / Regulatory Toxicology and Pharmacology 64 (2012) 51–67 61p = 0.001) – The main source of misﬁt arises from the reduced RR at
27.50 years compared to never smokers of 0.77 (0.63–0.94). Block
11 (CPS I, 20+/day, p = 0.002) – The main sources of misﬁt derive
from the steep drop in RR up to 0.5 years, with a shallower decline
later, and some evidence of a later rise between 7.5 and 15.0 years.
Block 28 (HRUBEC, females, p = 0.01) – Here the excess RR has vir-
tually disappeared after 3 years, but reemerges, almost to the level
of current smokers, after 7.5 and 12.5 years, before declining again.
Block 25 (HONJO, males, p = 0.02) – Little evidence of a decline is
seen up to 7.5 years, after which the RR declines. Block 26 (HONJO,
females, p = 0.02) – Again there is no evidence of a decline up to
7.5 years, but here the RR in shorter-term quitters (1 and 3.5 years)
is higher than in current smokers, though based on few cases.
Block 15 (CPS II, females, p = 0.04) – Here the RR declines steadily
up to 4.5 years, by which time it is at about the level of never
smokers. However, it rises again at 8.5 years, almost to the level
of current smokers, before declining again. It is notable that in all
the seven blocks mentioned the observed RRs do not show amono-
tonic pattern of decline with time quit, and the pattern of misﬁt is
quite variable between the misﬁtting studies. Over all studies com-
bined, the ﬁt to the model seems quite reasonable.
It should also be noted that in block 2 (ALDERS, males, 55–
74 years) the estimated SE of H, 728690, is very much larger than0.50 1.00 4.002.00 8
Block: Study Half life
95% CI
  1:ALDERS
  3:ALDERS
  4:ALDERS
  5:BOSETT
  *6:BRHS
  *7:CEDERL
  *8:CEDERL
  *9:CEDERL
  *10:CPSI
  *11:CPSI
  *12:CPSII
  *13:CPSII
  *14:CPSII
  *15:CPSII
  16:DOBSON
  17:DOBSON
  *18:DOLL
  *19:DOLL
  *20:DOLL
  *21:HAMMON
  *22:HAMMON
  *23:HIRAYA
  *24:HIRAYA
  *25:HONJO
  *26:HONJO
  *27:HRUBEC
  *28:HRUBEC
  29:INTERH
  *30:KAISER
  *31:KAISER
  32:NEGRI
  *33:NURSES
  *34:PAGANI
  *35:PAGANI
  36:ROSENF
  37:ROSENM
  38:TAVANI
  *39:TVERDA
  *40:WEN
  *41:WHITEH
Total (95% CI)
*prospective study
Fig. 1. Forest plot of half-life estimates. Tables 5 and 6 present results of inverse–variance
the original scale by taking exponentials. The individual study estimates and the 95% CI
graphical representation individual RRs are indicated by a solid square, with the area of
where the CI extends outside the range indicated. Also shown is the combined estima
diamond of standard height, with the width indicating the 95% CI.in any of the other blocks. This was the only block where the cur-
rent smoker RR was less than 1. In subsequent analyses this block
is ignored. As the statistical methods involve inverse–variance
weighting, this block would in any case have had effectively zero
weight.3.5. Heterogeneity between estimates of half-life
It is clear that there is considerable heterogeneity between the
estimates of H for the 40 blocks (omitting block 2). In 10 blocks the
estimate is less than two years, while in 12 it is more than 10 years.
To investigate heterogeneity further, attention was restricted to
those 33 blocks which showed no signiﬁcant (at p < 0.05) evidence
of misﬁt to their maximum likelihood ﬁtted H value, with addi-
tional analyses carried out (results not shown), in which ﬁxed H
values of 1, 2, 4.40 (the weighted mean), 5, 10 and 20 years were
ﬁtted to each block. All seven of those blocks where the ﬁtted H va-
lue was less than 2 years showed signiﬁcant misﬁt to ﬁxed values
of 10 or 20 years, while six out of eight blocks where the ﬁtted H
value was more than 10 years showed signiﬁcant misﬁt to ﬁxed
values of 1 or 2 years. In three of the remaining 18 blocks, with
intermediate ﬁtted H values, both high and low ﬁxed H values16.00 32.00.00
Half life
95% CI
5.18 (0.89, 30.31)
3.29 (0.63, 17.04)
2.98 (0.12, 72.36)
7.61 (1.56, 37.20)
3.17 (0.93, 10.84)
22.12 (0.53, 918.67)
9.03 (2.51, 32.52)
14.29 (2.10, 97.31)
1.97 (0.63, 6.16)
1.81 (1.14, 2.87)
4.10 (2.53, 6.63)
6.71 (3.48, 12.96)
0.52 (0.03, 8.34)
0.30 (0.03, 3.11)
2.17 (0.88, 5.39)
2.30 (0.90, 5.90)
1.60 (0.27, 9.70)
24.43 (6.30, 94.65)
17.41 (3.12, 97.12)
10.42 (3.54, 30.67)
29.08 (9.29, 91.07)
10.29 (2.16, 49.13)
3.30 (0.00, 3444.37)
12.62 (7.43, 21.44)
9.84 (3.32, 29.14)
7.28 (4.73, 11.22)
16.69 (10.23, 27.22)
4.71 (3.34, 6.65)
8.72 (2.48, 30.59)
12.95 (1.87, 89.71)
1.55 (0.58, 4.11)
1.67 (0.93, 2.99)
10.75 (4.69, 24.63)
23.92 (5.90, 96.99)
0.88 (0.44, 1.75)
0.88 (0.35, 2.21)
3.54 (1.10, 11.43)
1.18 (0.71, 1.97)
2.05 (0.16, 26.20)
8.01 (2.82, 22.77)
4.40 (3.26, 5.95)
weighted analysis of log H based on 40 blocks, with the estimates converted back to
are shown in Fig. 1, both numerically, and graphically on a logarithmic scale. In the
the square proportional to the weight (inverse–variance of log H). Arrows indicate
te, based on inverse–variance weighted analysis of log H. This is represented by a
Table 5
Weighteda estimates of H by various block characteristics.
Characteristic Level Nb pc H (95% CI)
All All 40 – 4.40 (3.26–5.95)
Study type Case-control 11 0.06 2.84 (1.65–4.89)
Prospective 29 5.26 (3.72–7.43)
Sex Male 25 0.15 5.19 (3.62–7.43)
Female 12 2.30 (1.08–4.87)
Combined 3 4.12 (2.03–8.36)
Continent North America 17 0.27 4.43 (2.97–6.60)
Europe 15 3.05 (1.51–6.16)
Asia 5 11.12 (4.03–31.06)
Australia 2 2.23 (0.50–9.92)
Multicountry 1 4.71 (2.15–10.32)
Publication year Before 1990 12 0.12 6.40 (2.50–16.38)
1990–1994 15 2.91 (1.76–4.79)
From 1995 13 5.31 (3.59–7.86)
Age at startd <50 12 <0.001 1.47 (0.91–2.39)
50–59 14 5.22 (3.79–7.20)
60–69 11 7.48 (4.56–12.28)
70+ 3 13.77 (4.28–44.35)
Smoking category All 32 0.73 4.68 (3.29–6.65)
Lighte 4 4.08 (1.57–10.62)
Heavyf 4 3.31 (1.44–7.62)
Smoking product Cigarettes only 12 0.32 4.01 (1.94–8.30)
Cigarettesg 17 3.91 (2.61–5.84)
Any producth 8 4.61 (2.35–9.06)
Unspeciﬁed 3 11.33 (3.85–33.31)
Current smoker RR <1.50 4 0.004 13.83 (4.04–47.34)
1.50–1.99 15 7.67 (4.90–12.00)
2.00–2.99 14 3.89 (2.44–6.21)
3.00–3.99 4 2.85 (1.68–4.85)
4.00+ 3 1.56 (0.66–3.67)
Cases in quitters <100 14 0.27 4.76 (1.92–11.82)
100–249 13 2.59 (1.35–4.98)
250–499 8 4.98 (2.67–9.27)
500–999 3 3.88 (2.13–7.07)
1000+ 2 7.16 (3.77–13.59)
a Based on inverse–variance weighted analysis of log H, with the estimates
converted back to the original scale by taking exponentials.
b Number of blocks; block 2 is not included as the current smoker RR is less than
1.0 and the SE of H is extremely high.
c Probability value for difference between groups.
d Midpoint of age range (at baseline for prospective studies).
e Light = 1–19 or 1–20 cigarettes/day (see Table 4).
f Heavy = 20 + or 21 + cigarettes/day (see Table 4).
g Cigarettes regardless of pipe and cigar smoking.
h Smoked cigarettes, pipes and/or cigars.
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the weighted mean H of 4.40 showed signiﬁcant misﬁt.
It is clear from Table 4 that, over the 40 blocks, there is a strong
relationship between the estimate of H and its SE. The mean SE is
0.64 for the 10 H values below 2.0, but rises to 3.00 for the 10 be-
tween 2 and 5 and to 4.49 for the eight between 5 and 10, reaching
13.42 for the 12 above 10. This suggests an approximate linear
relationship between H and its SE, and that heterogeneity analysis
would be better conducted based on estimates of log H.
Fig. 1 is a forest plot, giving the ﬁtted H values and their 95% CI
for each block individually and for the overall blocks combined.
The data for the individual blocks are taken from the values
returned from ﬁtting the negative exponential model. The overall
estimate of H of 4.41 (95% CI 3.25–5.96) is based on
inverse–variance weighted regression analysis of log H, with the
estimates back-transformed to the original scale. Table 5 shows
the individual relationship of nine block characteristics to the ﬁt-
ted H. No signiﬁcant (at p < 0.05) relationship was seen between
H and study type, sex, continent, publication year, smoking cate-
gory, smoking product or the number of cases in quitters, althoughthe tendency for H to be higher for prospective than for case-con-
trol studies was close to signiﬁcance (p = 0.06). The strongest rela-
tionship (p < 0.001) was the tendency for H to rise sharply with
increasing age at start of the study. The only other characteristic
signiﬁcantly predictive of log H was the current smoker RR
(p = 0.004), with H values clearly lower in blocks where the current
smoker RR was high. It should be noted that current smoker RR and
mean age at start are quite strongly negatively related, with the
correlation coefﬁcient 0.60 (p < 0.001).
Forward stepwise multiple regression analysis was also con-
ducted. As shown in Table 6, the ﬁnal model included mean age,
smoking category, study type and publication year, but not current
smoker RR. Estimates of log H increased with mean age. They were
lower for the eight blocks (from studies CPSI, CPSII and HAMMON)
where subjects were subdivided by amount smoked than for the
other blocks, but there was no evidence that estimates differed be-
tween the four blocks for lighter smokers (<20 or <21 cigarettes/
day) than for the heavier smokers (20 or 21+ cigarettes/day). Esti-
mates were also higher for prospective than case-control studies,
and for studies published before 1990. The deviance about the
mean of 196.31 on 39 d.f. reduced to 49.26 on 31 d.f. in the full
model.
3.6. Sensitivity analyses
Table 7 compares ﬁtted H values and goodness-of-ﬁt for the
main and the four sensitivity analyses.
In sensitivity analysis A, where the RR for the earliest quitting
period is removed from the block before ﬁtting the negative expo-
nential model, estimates of H are generally quite similar to those
from the main model. However, there were two obvious excep-
tions. These related to block 7 (CEDERL, age 40–49 years) and block
8 (age CEDERL, 50–59 years), where removal of the RR for 1–
9 years quitting left only one RR for quitting, which was below
1.0, so reducing the estimates from, respectively, 22.12 and 9.03
to 1.00. A similar situation pertained for block 24 (HIRAYA, fe-
males), although the reduction in the estimate was less, from
3.30 to 0.63. In block 14 (CPSI, females, <20 cigarettes/day), the ﬁve
quitting RRs left in sensitivity analysis A were close to 1.0, with no
evidence of a trend. In all these four blocks, the estimated SE of H
(not shown) was extremely high. As referred to earlier, there were
seven blocks in the main analysis where misﬁt occurred which was
signiﬁcant at p < 0.05. Five of these blocks remained signiﬁcant
misﬁts in sensitivity analysis A, but in block 11 (CPSI, 20+ ciga-
rettes per day) and block 28 (HRUBEC, females) the misﬁt was no
longer signiﬁcant.
In sensitivity analysis B, RRs for quitting periods of up to 2 years
are counted as relating to current smokers. This had no effect at all
for 23 of the 40 blocks, where the earliest period of quitting ex-
tended up to more than 2 years, but meant the omission of be-
tween one and four RRs in the other 17 blocks. As is evident
from Table 7, the estimates of H for these blocks are generally very
similar to the corresponding estimate from the main analysis, the
notable exception being block 15 (CPSII, females, 20+ cigarettes/
day) where the estimate of H increased from 0.30 to 7.62.
In the main analysis the midpoint time of the ﬁnal open-ended
interval was estimated as the mean of the lower limit and either
50 years or the upper limit of the age-range studied minus
20 years, if this was smaller than 50 years. The value of 50 years
in the above algorithmwas replaced by 30 years in sensitivity anal-
ysis C, and by 70 years in sensitivity analysis D. In sensitivity anal-
ysis C the midpoint time was reduced in 38 blocks and unchanged
in two, while in sensitivity analysis D the midpoint time was in-
creased in 21 blocks and unchanged in 19. While there were some
exceptions, the general effect was to decrease estimates of H
slightly in sensitivity analysis C and increase them in sensitivity
Table 6
Fitted weighted regression model for log H.a
Characteristic Level Estimate (SE) pb
Constant 0.805 (0.326) 0.019
Mean agec <50 Base
50–59 1.467 (0.257) <0.001
60–69 2.088 (0.297) <0.001
70+ 2.067 (0.474) <0.001
Smoking category All Base
Lightd 1.093 (0.344) 0.003
Heavye 1.094 (0.275) 0.003
Study type Case-control Base
Prospective 0.601 (0.213) 0.008
Publication year Before 1990 Base
1990–1994 0.997 (0.314) 0.003
From 1995 0.785 (0.311) 0.017
a Inverse–variance weighted. From forward stepwise procedure, successively
introducing mean age (p < 0.001), smoking category (p = 0.008), study type
(p = 0.01) and publication year (p = 0.01). The model allows the predicted H value
for any block to be calculated by adding up the estimates corresponding to the block
characteristics and then taking exponentials.
b For categorical characteristics, p values are relative to the base level.
c Midpoint of age range (at baseline for prospective studies).
d Light = 1–19 or 1–20 cigarettes/day (see Table 4).
e Heavy = 20 + or 21 + cigarettes/day (see Table 4).
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analysis C were by 34% in block 5, by 29% in block 22, and by
27% in block 9, while the largest proportional increases in H in sen-
sitivity analysis D were by 22% in block 20, and by 16% in blocks 23
and 35. Sensitivity analyses C and D had little effect on goodness-
of-ﬁt.
Overall weighted estimates of H based on the sensitivity analy-
ses varied only between 4.35 and 4.81, quite similar to the esti-
mate of 4.40 years for the main analysis.3.7. Study of HIV positive subjects
Petoumenos et al. (2011) described the results of a multi-centre
study conducted in Europe, Argentina, Australia and the USA
involving 27,136 HIV patients enrolled from December 1999 and
followed up to February 2008. Data on time of stopping or starting
smoking was not recorded, but patients reporting being a current
smoker on one visit and being a nonsmoker at the next were taken
to have quit halfway between the two visit times. Similarly pa-
tients restarting smoking were considered current smokers from
halfway between the relevant visits. The authors compared risk
of AMI (fatal and nonfatal) in never smokers, current smokers,
and quitters during follow-up by quit period, adjusted for cohort,
calendar year, age, sex and various indicators of cardiovascular risk
and HIV treatment. Converting these estimates to be relative to
never smokers using the method of Hamling et al. (2008) gives
RR (95% CI) estimates of 3.45 (2.59–4.59) for current smokers,
and of 3.79 (2.47–5.84), 3.03 (1.83–5.03), 2.66 (1.42–4.96) and
2.10 (1.18–3.75) for quitters during follow-up of <1, 1–2, 2–3 and
>3 years, respectively, based on a pseudo-number of 78.7 cases in
quitters. Using time midpoints of 0.5, 1.5, 2.5 and 4.5 years, H
was then estimated as 4.30 (SE 2.35) years, with no evidence of
misﬁt. This is close to the weighted mean of 4.40 years for the main
analyses. A quite similar estimate of 5.81 (SE 4.16) years was ob-
tained based on additional results provided by the authors for an
endpoint including CHD treated by an invasive coronary procedure
in addition to AMI, an endpoint which is somewhat different from
any used in the other studies.4. Discussion
4.1. Advantages of the negative exponential model
Although not derived from theoretical considerations, the neg-
ative exponential model has a number of attractions. It has a sim-
ple functional form, allowing the curve of the decline in excess risk
by time of quit to be quantiﬁed by a single parameter, H, with an
easily understood interpretation. Thus, if the RR from current
smoking is 3 so that the excess risk is 3  1 = 2, and H is estimated
as 5 years, one can readily see that the RR will be 1 + 0.5  2 = 2
after 5 years, 1 + 0.5  0.5  2 = 1.5 after 10 years, 1 + 0.5  0.5 
0.5  2 = 1.25 after 15 years, and so on asymptotically towards
1.0. Having an estimate of H and its SE also allows derivation of in-
verse–variance weighted combined estimates for a set of data
blocks, and comparison of estimates by block characteristics such
as sex, age or study type. Provided the model ﬁts the observed data
reasonably well, use of the negative exponential model should be a
useful tool for summarizing data in a meaningful way. As far as we
are aware, no one has previously attempted to use this or other
models to try to summarize the evidence on the decline in excess
risk following quitting.4.2. Fit to the negative exponential model
We ﬁtted the model separately for 41 data blocks, and found
that generally it did ﬁt the observed data well. It is perhaps unsur-
prising that the model should ﬁt data adequately for blocks which
are based on a limited number of time periods and relatively few
IHD cases in quitters, and where the RRs decline monotonically
with increasing time of quitting. However, as is evident from Table
4, it also ﬁts data from a number of blocks which are based on ﬁve
or more time periods and quite a substantial number of quitters,
and where there are some ﬂuctuations in the RRs as quitting time
increases. There are, as described in the results section, seven
blocks where a statistically signiﬁcant misﬁt was seen, but these
seem to be more a result of unusual patterns in the data, which
vary from study to study, rather than any general deﬁciency of
the model. Thus for example, the pattern of a lack of decline in
RR between about 4 and 17.5 years quit seen in block 29 (INTERH)
clearly differs from that seen in most other blocks, while the signif-
icant reduction in risk in long-term quitters compared to never
smokers in block 33 (NURSES) is also not generally evident else-
where. Even where the model does not ﬁt precisely, it still clearly
explains a very large part of the variation in RR by time of quit.4.3. Heterogeneity between estimates
While we feel that deriving an estimate of H using the negative
exponential model is in general a valid and useful way of data sum-
mary, one should bear in mind the clear evidence of heterogeneity
between estimates from different data blocks. Our overall estimate
of H of 4.40 (95% CI 3.26–5.95) years, based on 40 blocks (ignoring
block 2 where the RR for current smokers compared to never
smokers was less than 1.0) is clearly inconsistent with the data
for a number of blocks with lower or higher H estimates. Nor is
it consistent with the statement by the US Surgeon-General
(1990) that ‘‘the excess risk of CHD caused by smoking is reduced
by about half after 1 year of smoking abstinence’’, as an H of 1.0
signiﬁcantly (p < 0.05) misﬁts the data from almost half the blocks
studied, with the misﬁt highly signiﬁcant (p < 0.001) in about a
quarter. The heterogeneity we observed is more consistent with
the statement made in the IARC Monograph (2007) ‘‘Some studies
ﬁnd the risk to be similar to that in never smokers after 10–15
years abstinence, whereas others ﬁnd a persistent increased risk
Table 7
Comparison of ﬁtted H values and goodness-of-ﬁt for the main and sensitivity analyses.a
Blockb Main analysisc Sensitivity analysis Ad Sensitivity analysis Be Sensitivity analysis Cf Sensitivity analysis Dg
1 5.18 3.44 – 5.01 –
3 3.29 3.28 – 3.28 –
4 2.98 4.26 – 2.75 3.00
5 7.61 8.16 – 5.02 8.16
6 3.17 3.04 3.11 3.13 –
7 22.12 [1.00] – – –
8 9.03 [1.00] - 8.04 –
9 14.29 [14.75] – 10.40 –
10 1.97 2.08 2.10 1.98 1.97
11 1.81⁄⁄ 2.03 2.07 1.81⁄⁄ 1.81⁄⁄
12 4.10 4.10 4.24 3.70 4.24
13 6.71 6.76 7.11 6.37 6.40
14 0.52 0.03 1.70 0.52 0.52
15 0.30⁄ 0.56⁄ 7.62 0.30⁄ 0.30⁄
16 2.17 2.18 2.12 2.16 –
17 2.30 2.29 2.20 2.25 –
18 1.60 2.20 – 1.61 –
19 24.43 24.56 – 20.73 –
20 17.41 17.31 – 13.57 21.32
21 10.42 10.35 10.25 8.27 –
22 29.08 29.59 28.78 20.78 –
23 10.29 11.25 – 8.43 11.94
24 3.30 [0.63] – 3.12 3.34
25 12.62⁄ 12.60⁄ 12.76⁄ 10.61⁄⁄ 13.44⁄
26 9.84⁄ 9.79⁄ 9.61⁄ 8.58⁄ 10.36⁄
27 7.28 7.76 – 6.63⁄ –
28 16.69⁄ 17.16 – 13.17⁄⁄ 17.39⁄
29 4.71⁄⁄⁄ 5.24⁄⁄⁄ – 5.34⁄⁄⁄ 4.54⁄⁄⁄
30 8.72 9.74 – 7.60 9.27
31 12.95 14.04 – 11.16 14.28
32 1.55 1.76 1.83 1.55 1.55
33 1.67⁄⁄⁄ 3.20⁄⁄ – 1.67⁄⁄⁄ –
34 10.75 12.41 – 9.08 11.88
35 23.92 22.19 – 20.55 27.71
36 0.88 0.89 0.71 0.88 –
37 0.88 0.48 0.48 0.88 –
38 3.54 2.74 – 2.92 3.73
39 1.18 1.18 1.33 – –
40 2.05 1.66 – 2.07 –
41 8.01 8.27 – 8.78 –
Totalh 4.40 4.79 4.81 4.43 4.35
a The values shown in the table are the ﬁtted H values. Where there is evidence of misﬁt, this is indicated by: ⁄p < 0.05, ⁄⁄p < 0.01, ***p < 0.001.
b See Table 3 for details of the blocks. Block 2 is omitted as the current smoker RR was less than 1.0.
c Results as shown also in Table 4.
d Omitting the estimate in each block with the lowest quitting period. Estimates in square brackets are those for blocks where this omission left only a single RR for quitters.
e Counting estimates with an upper limit of quitting time up to 2 years as applying to current smokers. Dashes indicate where this did not affect the data considered.
f Midpoint time for the ﬁnal, open-ended, period of quitting which is estimated as the mean of the lower limit and either 30 years or the upper limit of the age range
studied minus 30 years, if this is smaller than 30 years. Dashes indicate where this did not affect the data considered.
g Midpoint time for the ﬁnal, open-ended, period of quitting which is estimated as the mean of the lower limit and either 70 years or the upper limit of the age range
studied minus 70 years, if this is smaller than 70 years. Dashes indicate where this did not affect the data considered.
h The inverse–variance weighted mean of log H, converted back to the original scale.
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overestimate the decline in risk, since a number of studies give
an estimated H of 10 to 20 years (see Table 7), and an increased risk
of 10–20% after 10–20 years is more consistent with our overall
estimate of H, than with the extreme at the high end. Note that
an H of 4.41 predicts an increased risk of 21% after 10 years and
4% after 20 years.
4.4. Sources of heterogeneity and data limitations
We discuss below various factors that might have contributed
to the observed variation between the estimates of H for the differ-
ent blocks, and to the difﬁculties in ﬁtting the negative exponential
model. However, none of these offer a clear explanation for it.
4.4.1. Accuracy of recording of smoking habits
In case-control studies, time of quit is normally based on re-
sponses by the subject (or in some cases a proxy respondent) ator shortly after the time of diagnosis of the disease. These re-
sponses are subject to inaccuracy of recall, which itself may be af-
fected by the diagnosis.
In prospective studies, time of quitting is normally based on re-
sponses given by the subject at baseline. While this again is open to
inaccurate recall, it should not be biased by knowledge of disease,
as the information is collected before onset of IHD. However, un-
less further interviews are carried out, which is rarely the situation,
the reported RRs are based on the assumption that smoking status
does not change during follow-up, ignoring the possibilities of later
quitting by current smokers, and later restarting by quitters. Note
that later starting by never smokers is a less important possibility
in the populations studied.
4.4.2. Updating of time quit
A problem in prospective studies concerns the categorization of
quitters by time of quitting. In most of the studies reporting re-
sults, risk is simply related to the time of quitting as reported at
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baseline will still be counted as having quit for 5–9 years at time
of IHD onset, which may be 10 to 20 years later. If risk declines
monotonically with actual time of quitting, H will therefore be
underestimated by the use of time of quitting as recorded at base-
line. The extent of this bias is difﬁcult to estimate, but will clearly
increase with increasing time of follow-up, though it will be com-
pensated to some extent by bias in the opposite direction if some
of the quitters resume smoking during follow-up. As noted earlier
two studies (DOLL and NURSES) did in fact update time of quit
based on the latest information from repeat interviews, while
two other studies (HRUBEC, WHITEH) updated time of quit in anal-
ysis, and one other study (HONJO) appeared to do so. However
these studies still produced highly variable estimates of H (see Ta-
ble 4), so this difference is not a ready explanation for the
heterogeneity.
4.4.3. Reverse causation
For lung cancer and COPD, IARC report (2007) clear evidence
that the risk in short-term quitters may be higher than in current
smokers, this observation being assumed to be due to ‘‘reverse cau-
sation’’, with smokers quitting shortly before diagnosis as a re-
sponse to precursor symptoms of the as yet undiagnosed disease.
There seems to be evidence of this in a number of the data blocks
we considered, though in some of these the observed increased risk
in short-term quitters may be a chance ﬁnding, especially where
there are few cases of IHD in this group. It should also be pointed
out that, as noted earlier, short-term quitters were excluded from
analysis in six blocks, and counted as current smokers in two, pre-
sumably as an attempt by the authors to avoid this bias. Our own
sensitivity analyses suggests that reverse causation in fact has little
effect on the estimated value of H, whether we excluded data from
each block for the earliest quitting time, or we counted as current
smokers all RRs within a block which related to a time of quitting
of up to two years. This is probably due partly to the relatively
small number of short-term quitters (as compared to current
smokers) and partly to the estimation of H being more dependent
on where the observed excess risk curve actually declines to half of
that from current smoking than on the precise shape of the curve
in the ﬁrst year or so after quitting.
4.4.4. Age of the subjects and risk from current smoking
It is clearly established that the RR for current smoking de-
creases markedly with increasing age (Lee, 2001). Our analyses
have shown that estimates of H signiﬁcantly (p < 0.001) increase
with increasing age of the subjects (at baseline in prospective stud-
ies), and also that estimates of H tend to be smaller where the cur-
rent smoking RR was higher, though the signiﬁcance of this
association disappeared when age of the subject was already taken
into account. One should be cautious about over-interpreting these
data. One would expect precise estimation of H to be more difﬁcult
where the current smoking RR is low, a difﬁculty illustrated by the
case of block 2 where the current smoking RR was less than 1.0,
and the estimation procedure was unreliable. Also there may be
a regression-to-the-mean effect, as chance over- or under-estima-
tion of the current smoking RR will, for a given set of quitting RRs,
correspondingly either under- or over-estimate H.
4.4.5. Estimating midpoints of time intervals
Another issue that should have an effect on the derived esti-
mate of H is the accuracy of the estimated time midpoints we used
for each quitting period. As the authors of the study never reported
such midpoints, we had to provide our own estimates, usually de-
rived as simple averages of the lower and upper extremes of the
range. Our sensitivity analyses do not suggest that use of alterna-
tive fairly extreme midpoints for the open-ended ﬁnal intervalmade much difference to the estimates of H, and certainly did
not explain the observed heterogeneity between estimates.
4.4.6. Use of pseudo-numbers
Our methodology for ﬁtting the negative exponential model re-
quires knowledge, for each block, of the numbers of cases and the
numbers of controls (or at risk) in each smoking group. As such
data are not provided, and indeed for covariate-adjusted data do
not exist in the strict sense, we used the method of Hamling
et al. (2008) to estimate a set of pseudo-numbers which corre-
spond exactly to the reported RRs and CIs. These pseudo-numbers
have been shown to allow accurate estimation of RRs and CIs rela-
tive to a different base group from that used originally, and we be-
lieve should be an adequate basis for estimation of H and
goodness-of-ﬁt to the model. This issue seems to us likely to be
of less concern than the other issues considered in the preceding
paragraphs.
4.4.7. Adjustment for smoking variables
Our method requires a set of RRs comparing risk in current
smokers, never smokers, and quitters by time of quit. For these
to be comparable, the RRs have to be adjusted for the same set of
variables, and as RRs relative to never smokers cannot be adjusted
for smoking variables, such as amount smoked, we restricted
attention to estimates that were adjusted for age and non-smoking
characteristics. This is in some ways unfortunate as it meant
excluding some analyses comparing risk of current smokers and
quitters which were adjusted for smoking variables. Clearly smok-
ers and quitters may differ by various smoking variables, as those
who quit may be the less ‘‘intense’’ smokers. Similarly, there may
be differences between those who quit for differing periods of
time. To test whether estimates of H actually vary by other smok-
ing variables using our methodology, one requires separate blocks
of RRs where the current smokers and quitters are restricted to
those with differing smoking habits. We identiﬁed four pairs of
blocks where members of one pair were lighter smokers (<20 or
<21 cigarettes per day) andmembers of the other pair were heavier
smokers (20 or 21+ cigarettes per day) but found no evidence that
estimates of H differed meaningfully between the lighter and hea-
vier smokers.
4.4.8. Applying the model to studies of diseased patients
The main analyses are restricted to populations without speciﬁc
diseases, mainly as we only found data for one study in a diseased
population, and we were unsure whether or not the pattern of de-
cline in risk following quitting varied by disease studied. Although
the estimate of H for this study of HIV patients happened to be
similar to our overall estimate, the data are clearly inadequate to
determine whether disease status affects the pattern of decline.
4.5. Extending the negative exponential model to other diseases
The usefulness of the negative exponential model could be fur-
ther tested by applying it to other diseases, including lung cancer,
chronic obstructive pulmonary disease [COPD] and stroke. For lung
cancer, there are a large number of relevant data sets and the high-
er RR for current smoking may afford better testing of the model.
For lung cancer, the multistage is another model which predicts
declines in excess risk following quitting (Lee, 1995), and it would
be of interest to see how similar the estimates of H from the two
models are.
4.6. A possible extension of the model
If the RR in current smokers is 1 + B, the negative exponential
model predicts that the RR for quitters for time t will be 1 + B
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(t loge2/H). Quitting can be viewed as switching from an expo-
sure of F = 1 unit (that of current smokers) to an exposure of
F = 0 units (that of quitters). Reexpressing RER(t) as F + (1  F)
exp (t loge2/H) allows for the possibility of modelling the effects
of switching to an exposure intermediate between 1 and 0. This
may have applications in studying the effects of switching to a re-
duced number of cigarettes per day, or of switching to a reduced
exposure product.
5. Conclusions
We identiﬁed 41 essentially independent data blocks from 23
studies, each block consisting of RRs for current smokers, never
smokers and quitters by time of quit, expressed relative to either
current or never smokers. Some studies provided separate blocks
by sex, age or amount smoked. For each block, we ﬁtted the decline
in excess risk following quitting using the negative exponential
model, and found that the ﬁt was generally adequate, misﬁt in
some blocks seemingly being due to block-speciﬁc unusual pat-
terns in the data, rather than any consistent deﬁciency of the mod-
el. While we were able to derive a combined estimate for H of 4.40
(95% CI 3.26–5.95) years, there was considerable heterogeneity be-
tween blocks, with H estimated as less than 2 years in 10 blocks,
and over 10 years in 12 blocks. Although H was found to increase
(p < 0.001) with mean age at start of the study, no clear relation-
ships were seen with study type, sex, or other block characteristics.
Conclusions were little affected by sensitivity analyses relating to
allowance for reverse causation, and to the estimates used in mod-
el-ﬁtting for the ﬁnal open-ended quitting period.
The negative exponential model has proved useful for ﬁtting the
pattern of decline in excess risk following quitting, and for summa-
rizing patterns reported in different studies and data blocks within
studies. Although ﬁtted estimates of H vary between studies for
reasons we cannot fully explain, and there are difﬁculties of ﬁtting
the model in the presence of reverse causation, our analyses
strongly suggest that the conclusion by the US Surgeon General
(1990) that ‘‘the excess risk of CHD caused by smoking is reduced
by about half after 1 year of smoking abstinence’’ is inconsistent with
the overall evidence, which we believe suggests a value of H more
like 4 to 5 years.
The negative exponential model should be studied further. It
could also prove useful for summarizing quitting data for lung can-
cer and other smoking-related diseases, and a modiﬁed version of
it may help to summarize data from studies of the effects of reduc-
ing amount smoked, and of switching to reduced exposure
products.
Conﬂict of interest statement
PNL, founder of P N Lee Statistics and Computing Ltd., is an
independent consultant in statistics and an advisor in the ﬁelds
of epidemiology and toxicology to a number of tobacco, pharma-
ceutical and chemical companies. This includes Philip Morris Prod-
ucts S.A., the sponsor of this study. JSF and JSH are employees of P
N Lee Statistics and Computing Ltd.
Authors’ contributions
PNL and JSF were responsible for planning the study. Literature
searches were carried out by PNL with the assistance of JSH. Data
entry was carried out by JSH and checked by PNL. Where appropri-
ate, difﬁculties in interpreting published data or in the appropriate
methods for derivation of RRs were discussed by all three authors.
Statistical analyses were conducted by JSF along lines discussedand agreed with PNL. PNL drafted the paper, which was then crit-
ically reviewed by JSF and JSH.
Acknowledgments
This research was funded by Philip Morris Products S.A. We
thank them for their support. However the opinions and conclu-
sions of the authors are their own, and do not necessarily reﬂect
the position of Philip Morris Products S.A. We thank Pauline Was-
sell, Diana Morris and Yvonne Cooper for assistance in typing the
various drafts of the paper and obtaining the relevant literature.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.yrtph.2012.
06.009.
References
Alderson, M.R., Lee, P.N., Wang, R., 1985. Risks of lung cancer, chronic bronchitis,
ischaemic heart disease, and stroke in relation to type of cigarette smoked. J.
Epidemiol. Community Health 39, 286–293.
Alderson, M.R., Lee, P.N., Wang, R., 1986. Risk of lung cancer, chronic bronchitis,
ischaemic heart disease, and stroke in relation to type of cigarette smoked,
passive smoking and other factors. www.pnlee.co.uk/reﬂist.htm [Download
ALDERS1986].
Baba, S., Iso, H., Mannami, T., Sasaki, S., Okada, K., Konishi, M., Tsugane, S., 2006.
Cigarette smoking and risk of coronary heart disease incidence among middle-
aged Japanese men and women: the JPHC Study Cohort I. Eur. J. Cardiovasc.
Prev. Rehab. 13, 207–213.
Ben-Shlomo, Y., Davey Smith, G., Shipley, M.J., Marmot, M.G., 1994. What
determines mortality risk in male former cigarette smokers? Am. J. Public
Health 84, 1235–1242.
Bosetti, C., Negri, E., Tavani, A., Santoro, L., La Vecchia, C., 1999. Smoking and acute
myocardial infarction among women and men: a case-control study in Italy.
Prev. Med. 29, 343–348.
Burns, D.M., Shanks, T.G., Choi, W., Thun, M.J., Heath, C.W., Jr., Garﬁnkel, L., 1997.
The American Cancer Society cancer prevention study I: 12-year follow-up of 1
million men and women, Changes in cigarette-related disease risks and their
implications for prevention and control. In: Shopland, D.R., Burns, D.M.,
Garﬁnkel, L., Samet J.M. (Eds.), Smoking and Tobacco Control. Monograph No.
8. US Department of Health and Human Services, National Institutes of Health,
National Cancer Institute, Rockville, Maryland, pp. 113–304 (NIH Publication
No. 97-4213) <http://cancercontrol.cancer.gov/tcrb/monographs/8/m8_3.pdf>.
Cederlöf, R., Friberg, L., Hrubec, Z., Lorich, U., 1975. The relationship of smoking and
some social covariables to mortality and cancer morbidity. A ten year follow-up
in a probability sample of 55,000 Swedish subjects age 18–69. Karolinska
Institute, Dept of Environmental Hygiene, Stockholm (Parts 1 and 2).
Cook, D.G., Pocock, S.J., Shaper, A.G., Kussick, S.J., 1986. Giving up smoking and the
risk of heart attacks: a report from the British Regional Heart Study. Lancet 2,
1376–1380.
Dobson, A.J., Alexander, H.M., Heller, R.F., Lloyd, D.M., 1991. How soon after quitting
smoking does risk of heart attack decline? J. Clin. Epidemiol. 44, 1247–1253.
Doll, R., Hill, A.B., 1956. Lung cancer and other causes of death in relation to
smoking. A second report on the mortality of British doctors. Br. Med. J. 2, 1071–
1081.
Doll, R., Hill, A.B., 1964. Mortality in relation to smoking: ten years’ observations of
British doctors. Br. Med. J. 1, 1399–1410.
Doll, R., Peto, R., 1976. Mortality in relation to smoking: 20 years’ observations on
male British doctors. Br. Med. J. 2, 1525–1536 (Erratum appears in BMJ
1980;971).
Friedman, G.D., Tekawa, I., Sadler, M., Sidney, S., 1997. Smoking and mortality: the
Kaiser Permanente experience, Changes in cigarette-related disease risks and
their implications for prevention and control. In: Shopland, D.R., Burns, D.M.,
Garﬁnkel, L., Samet, J.M. (Eds.), Smoking and Tobacco Control. Monograph No. 8.
US Department of Health and Human Services, National Institutes of Health,
National Cancer Institute, Rockville, Maryland, pp. 477–499 (NIH Pub. No. 97-
4213) <http://cancercontrol.cancer.gov/tcrb/monographs/8/m8_6.pdf>.
Garﬁnkel, L., Stellman, S.D., 1988. Smoking and lung cancer in women: ﬁndings in a
prospective study. Cancer Res. 48, 6951–6955.
Hamling, J., Lee, P., Weitkunat, R., Ambühl, M., 2008. Facilitating meta-analyses by
deriving relative effect and precision estimates for alternative comparisons
from a set of estimates presented by exposure level or disease category. Stat.
Med. 27, 954–970.
Hammond, E.C., Garﬁnkel, L., 1969. Coronary heart disease, stroke, and aortic
aneurysm. Factors in the etiology. Arch. Environ. Health 19, 167–182.
Hammond, E.C., Horn, D., 1958. Smoking and death rates – report of forty-four
months of follow-up of 187,783 men II. Death rates by cause. JAMA 166, 1294–
1308.
P.N. Lee et al. / Regulatory Toxicology and Pharmacology 64 (2012) 51–67 67Hirayama, T., Wahrendorf, J. (Eds.), 1990. Life-style and mortality: A large scale
census based cohort study in Japan. Contributions to epidemiology and
biostatistics. Karger, Basle (6).
Honjo, K., Iso, H., Tsugane, S., Tamakoshi, A., Satoh, H., Tajima, K., Suzuki, T., Sobue,
T., 2010. The effects of smoking and smoking cessation on mortality from
cardiovascular disease among Japanese: pooled analysis of three large-scale
cohort studies in Japan. Tob. Control 19, 50–57.
Hrubec, Z., McLaughlin, J.K., 1997. Former cigarette smoking and mortality among
US veterans: a 26-year followup, 1954–1980, Changes in cigarette-related
disease risks and their implications for prevention and control. In: Shopland,
D.R., Burns, D.M., Garﬁnkel, L., Samet, J.M. (Eds.), Smoking and Tobacco Control.
Monograph No. 8. US Department of Health and Human Services, National
Institutes of Health, National Cancer Institute, Rockville, Maryland, pp. 501–530
(NIH Pub. No. 97-4213) http://cancercontrol.cancer.gov/tcrb/monographs/8/
m8_7.pdf.
International Agency for Research on Cancer, 2007. IARC Handbooks of Cancer
Prevention, Tobacco Control, vol. 11: Reversal of Risk after Quitting Smoking.
IARC, Lyon, France.
Iso, H., Date, C., Yamamoto, A., Toyoshima, H., Watanabe, Y., Kikuchi, S., Koizumi, A.,
Wada, Y., Kondo, T., Inaba, Y., Tamakoshi, A., 2005. Smoking cessation and
mortality from cardiovascular disease among Japanese men and women. The
JACC study. Am. J. Epidemiol. 161, 170–179.
Kahn, H.A., 1966. The Dorn study of smoking and mortality among US veterans:
report on eight and one-half years of observation. In: Haenszel, W. (Ed.),
Epidemiological approaches to the study of cancer and other chronic diseases.
US Department of Health, Education, and Welfare. Public Health Service
National Cancer Institute, Bethesda, Maryland, pp. 1–125 (National Cancer
Institute Monograph 19).
Kawachi, I., Colditz, G.A., Stampfer, M.J., Willett, W.C., Manson, J.E., Rosner, B.,
Speizer, F.E., Hennekens, C.H., 1994. Smoking cessation and time course of
decreased risks of coronary heart disease in middle-aged women. Arch. Intern.
Med. 154, 169–175.
Kenﬁeld, S.A., Stampfer, M.J., Rosner, B.A., Colditz, G.A., 2008. Smoking and smoking
cessation in relation to mortality in women. JAMA 299, 2037–2047.
Kondo, T., Osugi, S., Shimokata, K., Honjo, H., Morita, Y., Maeda, K., Yamashita, K.,
Muramatsu, T., Shintani, S., Matsushita, K., Murohara, T., 2011. Smoking and
smoking cessation in relation to all-cause mortality and cardiovascular events
in 25,464 healthy male Japanese workers. Circ. J. 75, 2885–2892.
Lasdon, L.S., Waren, A.D., Jain, A., Ratner, M., 1978. Design and testing of a
generalized reduced gradient code for nonlinear programming. ACM Trans.
Math. Software 4, 34–50.
Lee, P.N., 1995. Studying the relationship of smoking to lung cancer using the
multistage model of carcinogenesis. A review. P N Lee Statistics and Computing
Ltd., Sutton, Surrey. www.pnlee.co.uk/reﬂist.htm [Download LEE1995D].
Lee, P.N., 2001. A review of the epidemiology of heart disease related to active
smoking. The role of amount smoked, age and time quit smoking. P N Lee
Statistics and Computing Ltd, Sutton, Surrey. www.pnlee.co.uk/reﬂist.htm
[Download LEE2001K].
Negri, E., La Vecchia, C., D’Avanzo, B., Nobili, A., La Malfa, R.G., 1994. Acute
myocardial infarction: association with time since stopping smoking in Italy. J.
Epidemiol. Community Health 48, 129–133.Paganini-Hill, A., Hsu, G., 1994. Smoking and mortality among residents of a
California retirement community. Am. J. Public Health 84, 992–995.
Petoumenos, K., Worm, S., Reiss, P., de Wit, S., d’Arminio Monforte, A., Sabin, C.,
Møller-Friis, N., Weber, R., Mercie, P., Pradier, C., El-Sadr, W., Kirk, O., Lundgren,
J., Law, M., 2011. Rates of cardiovascular disease following smoking cessation in
patients with HIV infection: results from the D:A:D: study. HIV Medicine 12,
412–421.
Rogot, E., Murray, J.L., 1980. Smoking and causes of death among US Veterans: 16
years of observation. Public Health Rep. 95, 213–222.
Rosenberg, L., Kaufman, D.W., Helmrich, S.P., Shapiro, S., 1985. The risk of
myocardial infarction after quitting smoking in men under 55 years of age. N.
Engl. J. Med. 313, 1511–1514.
Rosenberg, L., Palmer, J.R., Shapiro, S., 1990. Decline in the risk of myocardial
infarction among women who stop smoking. N. Engl. J. Med. 322, 213–217.
Tang, J.L., Cook, D.G., Shaper, A.G., 1992. Giving up smoking: how rapidly does the
excess risk of ischaemic heart disease disappear? J. Smoking-Related Disorders
3, 203–215.
Tavani, A., Bertuzzi, M., Negri, E., Sorbara, L., La Vecchia, C., 2001. Alcohol, smoking,
coffee and risk of non-fatal acute myocardial infarction in Italy. Eur. J.
Epidemiol. 17, 1131–1137.
Taylor, D.H., Hasselblad, V., Henley, S.J., Thun, M.J., Sloan, F.A., 2002. Beneﬁts of
smoking cessation of longevity. Am. J. Public Health 92, 990–996.
Teo, K.K., Ounpuu, S., Hawken, S., Pandey, M.R., Valentin, V., Hunt, D., Diaz, R.,
Rashed, W., Freeman, R., Jiang, L., Zhang, X., Yusuf, S., 2006. Tobacco use and risk
of myocardial infarction in 52 countries in the INTERHEART study: a case-
control study. Lancet 368, 647–658.
Tverdal, A., Thelle, D., Stensvold, I., Leren, P., Bjartveit, K., 1993. Mortality in relation
to smoking history: 13 years’ follow-up of 68,000 Norwegian men and women
35–49 years. J. Clin. Epidemiol. 46, 475–487.
US Surgeon General, 1979. Smoking and health. A report of the Surgeon General. US
Department of Health, Education, and Welfare; Public Health Service, Rockville,
Maryland. (DHEW Publication No. (PHS) 79-50066) http://
www.surgeongeneral.gov/library/reports/index.html.
US Surgeon General, 1990. The health beneﬁts of smoking cessation. A report of the
Surgeon General. US Department of Health and Human Services, Publich Health
Service, Centers for Disease Control, Center for Chronic Disease Prevention and
Health Promotion, Ofﬁce on Smoking and Health, Rockville, Maryland (DHHS
Publication No. (CDC) 90-8416) <http://www.surgeongeneral.gov/library/
reports/index.html>.
US Surgeon General, 2004. The health consequences of smoking. A report of the
Surgeon General. US Department of Health and Human Services, Centers for
Disease Control and Prevention, National Center for Chronic Disease Prevention
and Health Promotion, Ofﬁce on Smoking and Health, Atlanta, Georgia <http://
www.surgeongeneral.gov/library/reports/index.html>.
Wen, C.P., Cheng, T.Y., Lin, C.L., Wu, H.N., Levy, D.T., Chen, L.K., Hsu, C.C., Eriksen,
M.P., Yang, H.J., Tsai, S.P., 2005. The health beneﬁts of smoking cessation for
adult smokers and for pregnant women in Taiwan. Tob. Control 14 (Suppl. 1),
i56–i61.
